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Development of Long-acting Nanoformulated
Abacavir ProTides
Zhiyi Lin, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: Howard E Gendelman, M.D.
Combination antiretroviral therapy (cART) for treatment of human immunodeficiency
virus (HIV) infection demands life-long regimen adherence. Treatment interruptions lead
to a lack of virologic control and the emergence of viral mutations and drug resistance. To
address these, our laboratory developed long-acting (LA) parenteral administered
nanoformulated abacavir prodrug (NMABC) by formulating myristoylated abacavir (MABC)
with poloxamer 407 as stabilizer, which sustained ABC levels for up to 2 weeks with low
levels of active drug metabolite (CBV-TP). To more significantly extend the apparent halflife of ABC and improve its antiretroviral activities, we developed second generation longacting ABC prodrugs by ProTide technologies. This modification can deliver pre-activated
nucleoside analog inside the target cells. The work proceeded in defined manner.
First, we synthesized then characterized traditional ProTides of ABC, AlaMe, with
ProTide technology. The antiretroviral activity (EC50) of AlaMe was 7-fold lower then native
ABC. Then, AlaMe loaded and lipid coated PLGA nanoparticle was prepared withna size
of 250 nm by thin film hydration (NAlaMe). NAlaMe can be easily taken up and retained
by monocyte-derived macrophages (MDM) for weeks and protect MDM against HIV
infections. Male BALB/cJ mice were subcutaneously administered 54.3mg/kg ABC
equivalents of NAlaMe and ABC. NAlaMe treated mice had higher CBV-TP levels than
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ABC at 24 and 72 h after administration. These results showed that ProTide technologies
can be a useful strategy for the development of second-generation ABC LA.
Second, ProTide technology was combined with LA technology. Three ABC ProTides
(AlaMe, PheMe and PheC22) were successfully synthesized. AlaMe and PheMe were
traditional ProTides. PheC22 possessed a long-chain fatty alcohol moiety. All three
ProTides

demonstrated

improved

antiretroviral

activities

compared

to

ABC.

Nanosuspensions of PheMe (NPheMe) and PheC22 (NPheC22) were formulated using
P407 as stabilizer with sizes of 388 and 340 nm, respectively. Cell uptake, retention and
antiretroviral activity of NAlaMe, NPheMe, NPheC22 were tested in MDM. NPheC22 had
the highest uptake, retention and was able to protect MDM against HIV-1 infection up to
30 days. Combinatorial strategies thus show advantages for the development of secondgeneration ABC LA. ABC ProTides had long-chain fatty esters were specifically named
ABC ProTides LA.
Third, we investigated the influence of different combination of amino acid and longchain fatty alcohol on activities of ABC ProTides LA. Six ABC ProTides LA: AlaC14,
AlaC18, AlaC22, PheC14, PheC18 and PheC22 were synthesized and characterized. The
EC50 of ABC ProTides were up to 100- or 10-fold lower in MDM or CEM CD4+T cells
against HIV infection compared to ABC. CBV-TP was increased by up to 45-fold of 8-fold
in MDM or CEM CD4+T cells. Nanosuspension of all six ProTides were formulated using
DSPG-mPEG2K and Tween 80 as stabilizers. The six nanosuspension had sizes range
from 220 - 300 nm. Nanosuspensions were taken up, retained and released by MDM and
protected MDM against HIV-1 infection more than 28 days. PK studies in rats showed that
ProTide nanosuspension provide CBV-TP over a longer time than ABC. NAlaC18
provided clinically relevant CBV-TP levels in rats up to 7 days following a single injection.
In conclusion, ProTides and LA technologies were combinationally used to create second
II

generation ABC LA. These works are a step forward in the development of long acting
nucleoside reverse transcriptase inhibitors for human use.
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Chapter 1

Introduction
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1.1 HIV/AIDS epidemic
In June 5th, 1981, the U.S. Center for Disease Control (CDC) published an article
named “Pneumocystis Pneumonia – Los Angeles” in its Morbidity and Mortality Weekly
Report (MMWR). This article described 5 cases of a rare lung infection, Pneumocystis
carinii pneumonia (PCP) in young, white, previously healthy gay men. These men had
other unusual infections which indicated that their immune systems were dysfunctional.
That was the first official report of what later would become the Acquired
immunodeficiency Syndrome or AIDS and the disease epidemic as we know it today.
Two year later, Drs. Françoise Barré-Sinoussi and Luc Montagnier and their
colleagues at the Pasteur Institute in France reported the discovery of a retrovirus that
could be the cause of the new disease but it was Dr. Robert Gallo that firmly established
that the new virus now named the human immunodeficiency virus (HIV) was the cause of
AIDS. Drs. Françoise Barré-Sinoussi and Luc Montagnier won Nobel Prize in Medicine
and Physiology in 2008.
In May 1st, 1986, the International Committee on the Taxonomy of Viruses announced
the retrovirus that causes AIDS will be officially named as “Human Immuodeficiency Virus”
(HIV). In March 19th, 1987, almost six year after the first report on AIDS, the U.S. Food
and Drug Administration (FDA) approved the first medication zidovudine (AZT) for AIDS.
This drug was originally designed to treat cancer. In 1992, AIDS was the number one
cause of death for U.S. men ages 25 to 44. Then, it became the leading cause of death
for all Americans ages 25 to 44 in 1994. By October 31st, 1995, 500,000 cases of AIDS
have been reported in the U.S. Also, in 1995, FDA approved the first protease inhibitor
which brought in the era of combination antiretroviral therapy (cART), also called highly
active antiretroviral therapy (HAART), which changed the course of the disease to one of
certain death to a manageable chronic disorder.
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In 1996, Vancouver, Canada, the 11th international AIDS Conference highlighted the
effectiveness of HAART. The number of newly diagnosed AIDS cased in the U.S. was
declined for the first time since the beginning of the HIV/AIDS epidemic. In 1997, HAART
became the new standard of HIV/AIDS treatment. And the CDC reported first substantial
decline, a 47% decline as compared to the previous year, in AIDS death in the U.S.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 39 million
people out of the 76.1 million who had been infected have died of HIV/AIDS since the
beginning of epidemic. And there were still approximately 36.9 million people worldwide
living with HIV/AIDS in 2017.
1.2 HIV life cycle
As shown in Figure 1.1, there are seven stages of the HIV life cycle: 1) binding, 2)
fusion, 3) reverse transcription, 4) integration, 5) replication, 6) assembly and 7) budding.
In the first stage, virions bind to the target cell mediated by the viral envelope (Env)
with its primary receptor, the host protein CD41. Then, Env will change its conformation
and binds to coreceptors. There are two coreceptors and HIV strains can be broadly
classified based on their coreceptor usages. Viruses use chemokine coreceptor CCR5 are
termed R5, others use CXCR4 are termed X4, and viruses that use both coreceptors are
called R5X4. Coreceptor binding is widely thought to be the trigger that activates the
membrane fusion potential of Env, and the viral contents will be subsequently delivered
into the host cell cytoplasm. In the third stage, the viral single-stranded RNAs are
transcribed into double-stranded DNAs by reverse transcription (RT). Reverse
transcription is initiated shortly after virus entry: Viral DNA can be detected within hours of
infection. The rate of HIV-1 DNA synthesis had been measured in 293T cells and activated
primary human CD4+ T cells: minus-strand DNA is synthesized at a rate of ~70 nucleotides
per minute. Plus-strand DNA synthesis is rapid possibly because multiple initiation sites
3

are used2. Then, viral DNAs will be integrated into the host cell chromosome by virusencoded integrase protein. Once integrated, the proviral DNA will be replicated along with
cellular DNA during cell division cycles. The provirus serves as the template for
transcription of viral RNAs. Some viral RNAs are translated to yield the viral proteins,
whereas a portion of the full-length viral RNA is recruited to serve as genomic RNA in
progeny virions3.
HIV-1 virion assembly occurs at the plasma membrane, and all essential events are
mediated by HIV-1 Gag polyprotein including binding to the plasma membrane, making
the protein-protein interaction to create spherical particles, concentrating the viral Env
protein, and packaging the genomic RNA via direct interactions with the RNA packaging
sequence. The budding event that releases the virion from the plasma membrane is
mediated by the host endosomal sorting complexes required for transport (ESCRT)
machinery4.
1.3 Antiretroviral Drug (ARV)
Antiretroviral drug (ARV) is medicine for the treatment of infection by retroviruses,
primarily HIV. FDA have approved more than 30 ARV in seven mechanistic classes that
act on different stages of HIV life cycle. Nucleoside reverse transcriptase inhibitors
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the reverse
transcription of HIV. Protease inhibitors (PIs) block HIV protease that is essential for the
maturation of virions. Integrase inhibitors (INIs), also known as integrase strand transfer
inhibitors (INSTIs), stop HIV integration that mediate the integration of viral DNA to host
cell DNA. All other drugs include a fusion inhibitor, a CCR5 antagonist, and a CD4 postattachment inhibitor. In addition, two drugs, ritonavir (RTV or r) and cobicistat (COBI or c)
are used as pharmacokinetic (PK) enhancers.
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1.4 Combination Antiretroviral Therapy (cART)
Combination antiretroviral therapy (cART) is now recommended for everyone infected
with HIV starting immediately after diagnosis. Initial cART for a treatment-naïve patient
generally includes two NRTIs, usually abacavir/lamivudine (ABC/3TC), or tenofovir
alafenamide/emtricitabine (TAF/FTC), tenofovir disoproxil fumarate (TDF)/FTC, plus a
drug from one of three drug classes, an INSTI, an NNRTI, or a boosted PI. Coformulated
fixed-dose tablets consist of various combinations of ARV are developed to facilitate
adherence include Epzicom (ABC/3TC), Triumeq (DTG/ABC/3TC), Biktarvy (bictegravir,
BIC/FTC/TAF), etc.
1.5 Abacavir (ABC)
ABC is an NRTI approved by FDA under the brand name of Ziagen in 1998 and used
as either a 600-mg once-daily or 300-mg twice-daily regimen. ABC is rapidly absorbed
after oral administration with absolute bioavailability of ABC is approximately 83%. Food
do not significantly affect ABC exposure; therefore, ABC can be administered with or
without food5.
The in vivo metabolism of ABC is summary in Figure 1.2. ABC is extensively
metabolized by the liver with only 2% is excreted as unchanged drug in the urine. There
are two primary metabolism pathways for ABC. Metabolism by alcohol dehydrogenase
(ADH) results in the inactive carboxylate metabolite ABC-carboxylate (2269W93).
Metabolism by uridine diphosphate glucanosyltransferase (UGT) enzymes results in the
inactive glucuronide metabolite ABC-glucuronide (361W94). In a mass balance study
using [(14)C] abacavir, ABC and its two major metabolites accounted for the majority (92%)
radioactivity detected in plasma. 83% of the original dose was eliminated in the urine, and
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16% eliminated in feces. 36% radioactivity dose was identified as 361W94 and 30% was
identified as 2269W93 out of the 83% radioactivity dos eliminated in the urine6.
Concurrently, once inside the cell, ABC is phosphorylated to ABC monophosphate
(ABC-MP) by adenosine phosphotransferase, followed by deamination by a unique
cytosolic enzyme to cabover monophosphate (CBV-MP). Then, CBV-MP is converted to
CBV diphosphate (CBV-DP) and finally to CBV triphosphate (CBV-TP) by other kinases.
CBV-TP is the active metabolite, which competes with endogenous nucleotide 2’deoxyguanosine triphosphate for incorporation into the nucleic acid chain. And since it
lacks of the 3’-OH on the deoxyribose sugar, after incorporation, it will terminate the
synthesis of viral DNA chain by preventing addition of new base catabolized by HIV-RT7.
The terminal elimination half-life (t1/2b) of ABC is reported to be 2.59 hours which is not
clinically important because it is antiretroviral effect is due to CBV-TP, which has a long
t1/2b (20.64 hours)8.
CBV-TP is selective for the HIV-RT when compared with DNA polymerase a, b, g, and
e. The inhibition constant (Ki) of ABC for HIV-RT is 21 nmol/L. This Ki is 90-, 2900-, 1200,
and 1900-fold greater for DNA polymerase a, b, g, and e, respectively.
Clinical trials have shown that ABC, as part of an NRTI backbone, is generally well
tolerated. The most common drug-related adverse events are nausea, vomiting, fatigue,
headache, and diarrhea. The frequency of adverse events drops dramatically with
continued treatment.
Five percent of adult patients experience a hypersensitivity reaction (HSR) to ABC.
The symptoms include fever, rash, gastrointestinal symptoms (nauseam vomiting,
diarrhea or abdominal pain), generalized malaise or lethargy with or without concomitant
respiratory symptoms or other less frequent symptoms such as musculoskeletal
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symptoms and headache. HSR can be resolved without sequalae once abacavir was
discontinued and the patient should not be rechallenged. Studies suggested HSR is
strongly related to HLA-B*5701 allele carriage9-11. Treatment guidelines for HIV were
revised in 2008 to require (depending on region) or recommend HLA-B*5701 screening
for all patients before ABC treatment is initiated.
1.6 nanoformulated ART (nanoART)
1.6.1 Nanotechnology
Nanotechnology is the engineering and manufacturing of materials at the atomic and
molecular scale. Nanomedicine, according to National Institutes of Health (NIH), is the
application of nanotechnology to disease treatment, diagnosis, monitoring, and for
biological control. Rational design of nanoformulations for the delivery of therapeutic
agents including small molecule drugs, peptides or proteins, and genes are the most
active research areas for nanomedicine. Many reviews have been published to showcase
the management of HIV infection through application of nanoformulations12. The
nanoparticle sizes of researched nanoformulations range from 1 to 1000 nm, which give
them unique physical, chemical and biological properties that are distinct from those of
bulk materials or single molecules. For example, nanosized particles can provided higher
bioavailability of drugs because of the increased surface area followed by an increased
dissolution rate of the drug compounds according to the Noyes-Whitney equation.
Importantly, nanoparticles with smaller size and proper composition have the potential to
cross the blood brain barrier (BBB), delivering antiretroviral drugs (ARVs) to the brain, one
important anatomical reservoir for HIV.
Nanoformulations that have been used for the delivery of ARV can be roughly divided
to four categories: drug suspension (nanosuspension), polymer-based nanoformulation,
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lipid-based nanoformulation and inorganic nanoparticles. Nanosuspensions, also known
as drug suspension or nanocrystals, are sub-micron colloidal dispersions of pure particles
of drug, which are stabilized by surfactants13. It is the most promising type of
nanoformulation that can be used for the development of nanoART. Compared to other
nanoformulations, the key features of nanosuspensions are the minimal use of excipients
and the industrially feasibility. The former advantage implies both high drug content and
diminished excipient-related toxicity. For other nanoformulations, low drug loading,
potential excipient-related toxicity and manufacturing difficulties have severely
constrained clinical applications14,15.
Liposome, the first generation of nanoformulation and one of the most successful drug
delivery systems, was first described by Bangham and his co-workers in 1961 and the first
liposomal pharmaceutical product, Doxil®, received clinical approved in 1995. It took more
than 30 years for the liposomal pharmaceutical products to appear on the market. But it
was less than 10 years for the first nanosuspension product, Rapamune®, to be available
on the market after the first patent application of nanosuspension filed in the beginning of
1990s. Besides those two essential benefits that have been mentioned above, as one type
of nanoformulation, the sizes of nanosuspensions are usually between 200 to 600 nm,
which lead to enhanced dissolution, absorption, and bioavailability of drugs. This type of
naonoformulation has already been widely used for water insoluble drugs. But some
hydrophilic drugs undergo chemically modification to improve their hydrophobicity can also
be manufactured using this technique. Besides that, scientists recently developed novel
solid-in-oil nanosuspensions for hydrophilic drugs. Another prominent advantage of
nanosuspension is the reduced injection volume as a result of nearly 100% drug loading,
which is essential for intramuscular (IM), subcutaneous (SC) administration, namely depot
injections, that allow the nanosuspension to releases its active therapeutic agents in a
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consistent way over a long period of time to further improve the sustained release profile
of the drugs. However, it can also be administrated through other routes like oral, topical,
intravenous, ocular and pulmonary routes16.
Nanosuspension can be prepared by two basic methods, bottom-up technology and
top-down technology. Bottom up technology is an assembling method to form
nanoparticles by precipitation. Top down technology involves the particles size reduction
of large particles, which comprises high-pressure homogenization and bead/pearl milling
methods. However, the combination techniques, pre-treatment followed by a size
reduction step, are also being employed. The ingredients used in the formulation of
nanosuspension include crystalline active therapeutic agents along with stabilizers
(surfactants, polymers), tonicity agents (salts, sugars), cryoprotectants and solvents.
1.6.2 Preparation and characterization of nanoART
A variety of nanosuspensions17 were prepared for crystalline indinavir (IDV), ritonavir
(RTV), ATV, and efavirenz (EFV) by wet milling. The influence of the physical
characteristics of these formulations, including particle size, surfactant coating, surface
charge and shape, on the cell uptake, release and antiretroviral efficacy were evaluated
in a monocyte-derived macrophage (MDM) in vitro testing system. It was concluded that
drug type, surfactant coating, and shape demonstrated profound impact on particle uptake,
drug release, and antiretroviral activity while particle charge and size only had minor
effects. For example, it was shown that nanoparticle with longer rod-like shaper were
taken up more rapidly that short rods and spherical particles were taken up even slowly
than short rods.
Several different nanoformulations 18 were manufactured for crystalline IDV, RTV, ATV,
and EFV by three different methods included wet milling, homogenization and sonication
using a variety of excipients and the properties of these formulations were compared by
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using an established MDM scoring indicator system. The results showed that the
manufacturing methods affected the physicochemical properties of the nanoformulations.
The IDV nanosuspension were the most diverse with sizes of 252 and 418 nm and charges
of -40.6 and -15.1 mV, manufactured by wet milling and homogenization respectively, and
the IDV PLGA nanoparticles prepared by sonication had a size of 367 nm and a charge
of -9.6 mV. Different preparation methods and excipients also affected the biological,
immune, virologic, and toxicological properties of these formulations demonstrated by
mixed results from drug uptake, retention, release, and antiretroviral activity studies. For
example, in vitro cell uptake study, ATV concentration in cells after 8 hours incubation was
3- to 4-fold lower following PLGA nanoparticles treatment than that for homogenized or
milled particles. However, it is shown that the most significant difference affect cell
targeting and antiretroviral activity of nanoparticles was the drug itself. Based on those
results, it was proposed that the clinical utility of nanosuspension might depend on the
choice of drug and formulation composition.
1.6.3 Subcellular nanoART distribution
Intracellular trafficking19 of RTV nanosuspension from the point of initial uptake to final
release in MDM was investigated. It was shown that most nanoparticles taken up by MDM
through clathrin-dependent endocytosis were sorted into a recycling pathway, from early
endosome to recycling endosome, while bypassed lysosomal degradation, and drugs
finally were released intact from MDM without reduction in antiretroviral efficacy. siRNAs
against Rab8, Rab11, Rab14 and brefeldin-A (BFA), a disruptor of recycling and secretory
activities, were used to disrupt this pathway. Compared to untreated, siRNA scrambleand Rab8 siRNA-treated MDMs, Rab11 and Rab14 siRNA treated cells retained more
drugs and released fewer drugs into the media. MDM treated with BFA showed similar
impaired drug release, resulting in aggregation of nanoparticles in the perinuclear region.
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Proteomic and biological analysis suggested that particle recycling was primarily Rab11
regulated. Interestingly, it was shown that intact nanoparticles could be released from
MDM with same size and shape as the original particles and maintained the antiretroviral
activities. These results suggested the potential and advantages of targeting macrophage
for cell-based drug delivery.
A further study20 demonstrated that ATV nanosuspension (nanoATV) enhanced drug
antiretroviral efficacy by improving the establishment of the subcellular drug depots and
altering drugs distribution toward sites of active viral replication (Figure 1.3). Late and
recycling endosome compartments were pull down by immunoaffinity chromatography
with Rab-specific antibodies conjugated to magnetic beads and ATV nanoparticles were
seen in these subcellular compartments. It was discovered that nanoATV persisted in
Rab7+ late endosomal compartments of HIV-1 infected MDMs, the site of active viral
assembly, while most of nanoparticles stored in Rab11+ recycling endosomes of
uninfected MDMs. These results were cross validation by immunofluorescent staining of
these compartments for confocal microscopy. Since infectious HIV-1 released from MDM
are assembled in late endosomes, such colocalization between HIV and nanoATV in
subcellular compartments might provide additional benefits in restricting viral replication.
Thus, it was reasoned that the action of nanoART could be amplified by directing nanoART
to the late endosomal sites operative for viral assembly21.
Quantitative SWATH-MS proteomics22 was applied to investigate cellular proteins that
are deregulated by native ATV or nanoATV with or without HIV-1 infection in MDMs. The
results showed that HIV-1 and nanoATV engaged endolysosomal trafficking for assembly
and depot formation, respectively. Compared to virus, nanoATV oppositely regulated
endolysosomal proteins. For example, in nanoATV-treated HIV-1 infected MDMs, Rab5
and Rab7 were down-regulated, while up-regulation of these proteins was observed in
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HIV-1 infected MDMs. DAVID and KEGG bioinformatics were used to analyze the
proteomic data and the relationships between secretory, mobility and phagocytic cell
functions and virus and particle trafficking were shown. In this study, a previously unknown
mechanism for how long-acting nanoART provides a strategic advantage to combat viral
infection was discovered.
1.6.4 Cabotegravir (CAB) LA and Rilpivirine (RPV) LA
GlaxoSminthKline is the leading pharmaceutical company for the development of longacting nanoART for HIV treatment and prevention23. They developed a long-acting
injectable nansuspension that had 200 nm median particle size for Cabotegravir
(GSK1265744), an integrase inhibitor, by using wet milling technology. They reported that
in the phase I study of this nanoformulation, following single IM or SC injection, the mean
plasma level concentration of Cabotegravir remained well above the PA-IC90 for about or
longer than 24 weeks for dose of at least 200 mg. And Cabotegravir was still detectable
in plasma up to 48 weeks. Further clinical trials for the evaluation of the safety, tolerability,
and acceptability of GSK1265744 long-acting injectable formulation (744 LA) in adult male
subjects is ongoing. Long-acting injectable nanosuspension, called TMC278 LA, for
rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) was also
developed24. The free base of RPV was a stable crystalline polymorphic drug substance
with very low water solubility. Its nanosuspersions could be easily manufactured by wet
milling technology. The average particles sizes of nanosuspensions were 200, 400 and
800 nm and all of them were stable over 6 months. Following single dose administration,
the plasma concentration profiles showed sustained release of RPV over 3 months in dogs
and 3 weeks in mice. Compared to 400 and 800 nm nanosuspensions, 200 nm
nanosuspension achieved higher and more stable plasma concentration profiles, acted as
long-acting injectable nanoformulation. In a further preclinical investigation25, 200 nm
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nanosuspension of TMC278 was administered in rats and dogs as single IM or SC
injection. RPV showed sustained and dose-dependent release over 2 months in rats and
over 6 months in dogs. In the IM injection groups, the RPV concentrations in the lymph
nodes exceeded the plasma concentrations by over 100-fold one month after
administration, then decreased to 3- to 6-fold of the plasma concentrations 3 months after
administration. It was suggested that such observation was due to the nanoparticle’s
uptake by macrophages, and then the establishment of secondary depots in lymph nodes.
In the phase I study of TMC278 LA, single 400 mg and 600 mg doses, administrated
subcutaneously around the umbilicus or intramuscularly in the gluteus maximus muscle,
gave prolonged RPV plasma exposure of approximately 20 ng/mL after 8 weeks without
serious adverse events. The combination uses of 744 LA and TMC278 LA were also
clinically evaluated. In a phase III clinical trial, the study results showed that the
combination use of this two LA, injected once a month, had similar efficacy to a standard
of care, daily, oral three-drug regimen at week 48.
1.7 Long-acting slow effective release antiretroviral therapy (LASER ART)
In recent years, LASER ART have been developed in our labs to further improved the
pharmacokinetics and pharmacodynamics of nanoART26. The main idea of LASER ART
is modification of ARV to improve the its chemical, physical and biological properties to
achieve higher drug loading into nanoparticles, slower dissolution rate, longer apparent
half-lives, better viral reservoir penetration and eventually excellent patient treatment
adherence.
1.8 Significance of current projects
NRTIs served as the “backbone” of antiretroviral drug regimen. Generally, two NRTIs
are used along with a drug from other classes. But, the dosing frequency of LA reagent is
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determined by the drug’s aqueous solubility/hydrophobicity, antiretroviral potency/daily
dose and system clearance/half-life27 which means all the approved NRTIs are not suited
for redevelopment as long-acting injectable products using conventional pharmaceutical
manufacturing approaches. For example, the solubility, EC50/daily dose and half-life of
abacavir (ABC) are 2 mg/ml, 0.07 to 5.8 μM/600 mg (8.6 mg/kg), 1.54 h, while they were
0.1 mg/ml, 0.22 to 1.3 nM/0.30 mg (0.4 mg/kg), 40 h for CAB. It is worth noting that CBVTP, the active triphosphate metabolite of ABC, has half-life of 20 h which supported the
daily dose of ABC. However, in order to achieve equivalent therapeutic drug exposure for
LA formulation when compared with daily, oral version of NRTIs, the solubility and antiviral
potency of NRTIs definitely need to be adjusted in scale of one or two orders of magnitude.
We have reduced the solubility of ABC by conjugating it with myristoyl chloride (MABC)
and successfully nanoformulated MABC by high pressure homogenization28. Detectable
level of ABC was observed during the whole 14-day time period in vivo study, while the
CBV-TP level was not ideal29. Clearly, the antiretroviral activity of ABC also needs to be
adjusted.
In this project, we proposed to combine ProTide technology with our technologies of
long-acting nanoformulation development to generate second-generation of ABC LA. First,
we proved that ProTide technology which deliver pre-activated monophosphate of ABC
into the cells was able to improve the potency of drugs. Second, we demonstrated ProTide
technology can be used in combination with our technologies for the development of
second generation of ABC LA. Third, we discussed the optimization of such combination.
In summary, this project provided a new strategy for the development of NRTIs LA include
ABC LA for the treatment and prevention of not only HIV/AIDS but other disease.
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Figure 1.1 Life cycle of HIV (https://aidsinfo.nih.gov/).
The figure illustrates the main steps in the HIV-1 replication cycle: binding to the CD4
receptor and co-receptors; fusion with the host cell membrane; uncoating of the viral
capsid; release of the HIV RNA and proteins into the cytoplasm; reverse transcription of
HIV RNA to DNA; and translocation into the nucleus. Once inside the nucleus, the viral
DNA is integrated into the host DNA so HIV can use host cell machinery to make new viral
RNA and viral proteins that translocated to the cell surface to assemble into new immature
virus forms. The new viruses bud off and covert to its mature form.

15

Figure 1.2 Metabolic pathway of abacavir (ABC).
Once inside the cells, ABC is stepwise phosphorylated by intracellular kinases and
converted to its active metabolite CBV-TP to inhibit the synthesis of viral DNAs.
Concurrently, it will also be metabolized mainly in liver by UGT and ADH enzymes to its
inactive metabolites and eliminated in urine and feces30.
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Figure 1.3 Intracellular pathway of HIV-1 and nanoATV.
NanoATV enters MDMs via clathrin-coated pits and is then transported to the early
endosome. Then most of the nanoparticles are transported to the Rab11+ recycling
endosome in uninfected MDMs while most of the nanoparticles persisted in Rab7+ late
endosomal compartments in HIV-1 infected MDMs, the site of active viral assembly.
Modified with permission from literature20.
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Chapter 2
Development of a Nanoformulated ABC ProTide
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2.1 Abstract
Abacavir (ABC) ProTide AlaMe was synthesized based on ProTide technology with
high yield. The antiretroviral activity (EC50) of AlaC1 was 23.9 nM, when measured in MDM
against HIV-1ADA and was significantly improved as compared to ABC (161.7 nM). Lipid
coated PLGA nanoparticle loaded with AlaMe (NAlaMe) was prepared using thin-film
hydration. The size, PdI, and zeta-potential of NAlaMe measured by Zetasizer was 256
nm, 0.2 and -51 mV, respectively. Cell uptake and retention study of NAlaMe and AlaMe
was tested in MDM. In 8 h uptake study, highest uptake of NAlaMe was observed at 8 h
time point as 2671.1 ng/ml which was 275-fold higher that the uptake of AlaMe. In a 15day retention study, for AlaMe free drug treatment group, AlaMe level was under
detectable level since Day 1, while for NAlaMe treatment group, AlaMe levels were 436.2,
337.5, 58.0 and 20.3 ng/ml at day 1, 5, 10 and 15 after treatment. The extended retention
of AlaMe translated to improved antiretroviral efficacy results, NAlaMe was able to protect
MDM against HIV-1 infection up to Day 10 revealed by both P24 staining and RT assay.
In vivo pharmacokinetic study showed that NAlaMe was able to provide higher levels of
CBV-TP in both PBMC and tissues. Pharmacodynamic study of NAlaMe also showed
certain improvement in antiretroviral activity as compared to ABC. In conclusion, ProTide
technology was able to improve the drug potency both in vitro and in vivo, and might be
useful for the development of second-generation ABC LA.
2.2 Introduction
NRTIs include ABC need to be activated by a number of nucleoside and nucleotide
kinases in a stepwise manner resulting in the formation of the mono-, di-, and
triphosphoralyated nucleoside analogue metabolites to exert their therapeutic effects.
Factors limit the potency of NRTIs include, but not limit to, their poor affinity to the kinase
which leads to inefficient formation of the active triphosphate metabolites, and their polarity
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which leads to low membrane permeability and poor bioavailability. It was proposed that
delivering phosphorylated metabolites of the NRTIs would addressee some of these
limitations.
Numerous prodrug technologies have been proposed to deliver monophosphate into
the cells. Among them, ProTide technology which developed by Prof. Chris McGuigan
was a huge success and had led to at least 10 clinical candidates and two FDA-approved
drugs, TAF1 and sofosbuvir. Remarkably, TAF is 1,000 times more potent than TFV and
10 time more potent that the prodrug TDF2.
In this chapter, we discussed the possibility of employing ProTides technology to
develop second generation of ABC LA. We synthesized ABC ProTides and loaded it into
lipid coated PLGA nanoparticles (NAlaMe). It’s in vitro and in vivo behaviors were
investigated.
2.3 Results
2.3.1 Synthesis of ABC ProTides
AlaMe.was successfully synthesized according to ProTide technology (Figure 2.1).
On a scale of 1 g (3.492 mmol) of ABC, 1.4 g (76 %) of AlaMe product was formed: 1H
NMR (500 MHz, CD3OD): 7.66 (d, J = 6.6 Hz 1H), 7.10-7.40 (m, 6H), 6.15 (dd, J = 13.7,
5.7 Hz 1H), 5.97 (br, 1H), 5.53 (br, 1H), 4.08-4.30 (m, 2H), 3.85-4.0 (m, 1H), 3.23 (s, 3H),
3.21 (br, 1H), 2.93 (br, 1H), 2.81 (td, J = 16.9, 8.3 Hz 1H), 1.65-1.80 (m, 1H), 1.20-1.40
(m, 4H), 0.85 (app. d, J = 5.8 Hz 2H), 0.62 (br, 2H). 13C NMR (125 MHz, CDCl3): δ 175.4,
161.7, 157.4, 152.2, 138.1, 137.2, 131.7, 130.6, 126.1, 123.7, 121.4, 114.8, 70.1, 60.5,
52.7, 51.5, 47.1, 35.4, 24.3, 20.8, 20.5, 14.5, 7.6.
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P NMR (202 MHz, CD3OD); 3.87,

3.58. MS-ES+ (m/z): calcd. for C24H30N7O5P, 527.20 (100%), 528.21 (26.0%), 529.21
(2.7%); found, 528.2 [M+H+].
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2.3.2 Antiretroviral activity of AlaMe
Then we measured the antiretroviral activity of AlaMe and ABC in MDM against HIV1ADA (Figure 2.2). The antiretroviral activity (EC50) was 23.9 and 161.7 nM for AlaMe and
ABC, respectively. The EC50 of AlaMe was 7-fold smaller as compared to ABC, which
means the antiretroviral potency of AlaMe is significant improved by ProTide technology
as previously reported3.
2.3.3 Preparation and characterization of NAlaMe
PLGA nanoparticles have been used to deliver all kinds of drugs include proteins,
genes and other small molecules, owing to their attractive properties of biodegradability,
biocompatibility, ease of processing and sustained release4. However, its surface property
of PLGA nanoparticles limits its cellular membrane permeability, resulting in poor cell
uptake and efficiency in in vitro experiments. Lipids include synthetic phospholipids can
be coated on the surface of PLGA nanoparticles through electrostatic attraction and
hydrophobic interaction and significantly increase the stability, cell uptake and efficiency
of nanoparticles5. Lipid coated PLGA nanoparticles loaded with AlaMe were successfully
prepared by thin-film hydration methods (Figure 2.3A). The Deff, PdI, and zeta-potential
of NAlaMe measured by Zetasizer was 256 nm, 0.2 and -51 mV, respectively. TEM
imaging showed the nanoparticle of NAlaMe had spherical shape (Figure 2.3B). The drug
loading was calculated as 3%.
2.3.4 Cytotoxicity, uptake and retention of NAlaMe in MDM
The cytotoxicity of AlaMe and NAlaMe was investigated in MDM using CCK-8 kit and
ABC was served as a control. No significant cytotoxicity has been observed until 400 μM
for ABC, AlaMe and NAlaMe (Figure 2.4). Based on the result, 100 μM was selected for
other cell-based studies.
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MDM was treated with 100 μM of NAlaMe for 8 h, and AlaMe free drug was used as a
control. The uptake of NAlaMe was increased rapidly during the first 2 h, and AlaMe level
was 1987 ng/ml at 2 h (Figure 2.5A). At 8 h, AlaMe level slowly increased to 2671 ng/ml.
It is possible that the MDM has already be saturated with NAlaMe nanoparticles at the first
several hours. AlaMe level for free drug treatment group was substantially lower than the
nanoparticle treatment group with a peak level 22 ng/ml appeared at 2 h. These results
suggested that lipid coated PLGA nanoparticles can be used to facilitate the delivery of
ABC ProTides into the MDM.
In the retention study (Figure 2.5B), we also observed significant difference between
AlaMe free drug and NAlaMe treatment group. For free drug treatment group, AlaMe level
was under detectable level since day 1 while for NAlaMe treatment group, AlaMe level
stayed above the detection level during the whole study. At day 15, the drug level was 20
ng/ml for NAlaMe treatment group.
2.3.5 In vitro antiretroviral study
Next, we wanted to see whether sustained retention of AlaMe in MDM for the NAlaMe
treatment group will leads to sustained antiretroviral effect. In vitro antiretroviral study was
conducted in MDM for ABC, AlaMe free drug and NAlaMe.
Viral breakthrough was observed for ABC treatment group at day 1 (Figure 2.6-2.7).
For AlaMe free drug treatment group, since AlaMe was more potent as mentioned above,
total inhibition of viral growth at was observed at day 1. Partial inhibition of viral replication
was observed for AlaMe free drug treatment group until day 10 as RT assay showed
significant lower RT activity. For NAlaMe treatment group, total viral growth inhibition was
observed up to day 10 with partial viral breakthrough at day 15 (24.8% RT activity as
compared to the positive control). These results suggested that ABC ProTide AlaMe can
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protected MDM longer that ABC, and loaded AlaMe into lipid-coated PLGA nanoparticles
further improved this sustained protection effect.
2.3.6 Pharmacokinetic study of ABC and NAlaMe
Male BALB/cJ mice were subcutaneously administered 54.3mg/kg ABC equivalent
dose of ABC or NAlaMe. The CBV-TP levels in PBMC for ABC and NAlaMe were 76.8
and 93.3, 9.8 and 35.7 and 0.6 and 2.4 fmol/10^6 cells at 2 h, 24 h and 72 h after treatment,
respectively (Figure 2.8A). The CBV-TP levels for both groups fell below detection level
(Figure 2.8B-C) at day 7. CBV-TP could also be detected in spleen and lymph nodes 2 h
after treatment for both groups. For spleen, the CBV-TP levels were 9.2 or 49.6 fmol/10^6
cells for ABC or NAlaMe, respectively. For lymph nodes, the CBV-TP levels were 0.8 or
4.6 fmol/10^6 cells for ABC or NAlaMe, respectively. These results showed that NAlaMe
was able to deliver CBV-TP for a longer period of time. Moreover, higher levels of CBVTP were accumulated in spleen and lymph nodes, which suggested that the nanoparticle
preferably enter lymphatics system and might be beneficial for the ART.
2.3.7 Pharmacodynamic study of ABC and NAlaMe
To determine whether the improved PK profile of NAlaMe could translate into improved
antiretroviral efficacy, NSG mice were reconstituted with human PBL, a single
subcutaneously injection was administered of ABC or NAlaMe at 54.3mg/kg ABC
equivalents dose on day 10, followed by challenging with HIV-1ADA on day 11, and
necropsy 10 days after HIV-1 challenge. Blood and tissues were collected to determine
CD4/CD8 ratio, HIV-1p24 expression, and viral RNA/DNA. Flow cytometry analysis
showed that both ABC and NAlaMe treatment protected the animals from HIV-1-induced
CD4+ T cell loss to certain degree with NAlaMe showed better protection (Figure 2.9A).
Immunohistochemical analysis revealed that 1/7 animals in the NAlaMe treated group
were HIV-1p24 negative in spleen, and 1/7 animal only showed negligible infection while
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HIV-1p24 positive cells were observed in all the ABC treated mice and untreated HIV-1
control animals (Figure 2.10). In spleen, lung, lymph node, NAlaMe treatment reduced
viral RNA compared to ABC treatment or HIV-1 positive controls (Figure 2.9B-F).
2.4 Discussion
We confirmed that ProTide technology can be used to increase the potency of ABC. It
was suggested that there are not rate-limiting steps present in either the phosphorylation
pathway of abacavir or the activation of ABC ProTide. And all the cellular enzymes
involved in the conversion of ABC ProTide to CBV-TP (i.e., carboxylesterase(s),
phosphoramidase, ABC-MP deaminase, and the nucleotide kinases such as CMP kinase
and NDP kinase) are not metabolically saturated when extracellular drug concentrations
are as high as 100 μl. This means that increasing cellular delivery of higher ABC-MP
concentration through ProTide technology will concomitantly result in higher eventual
CBV-TP6. Indeed, AlaMe and NAlaMe showed improvement in in vitro antiretroviral study
and NAlaMe showed improvement in both pharmacokinetic and pharmacodynamic profile
as compared to ABC. Based on these results, we concluded that ProTide technology can
be used as a part of LASER ART for the development of LA formulation.
The limitations are, first, the low drug loading of lipid coated PLGA nanoparticle which
means large amounts of polymers need to be administrated along with the drugs which
might intensify local inflammation and is hard to achieve industrial production scale.
Second, because of the comparable hydrophilicity properties of AlaMe, it was quickly
released from PLGA nanoparticles and CBV-TP level could not be detected after day 3
for NAlaMe treatment group, which is not ideal for LA formulations.
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2.5 Methods
2.5.1 Reagents
Reagents were obtained from commercial sources and used directly; exceptions are
noted. Abacavir was purchased from BOC Sciences Inc. (Shirley, NY). Phenyl
dichlorophosphate, L-alanine methyl ester hydrochloride salt, dichloromethane (CH2Cl2),
chloroform (CHCl3), triethylamine (Et3N), diethyl ether, tetrahydrofuran (THF), tertbutylmagnesium chloride solution (tert-BuMgCl, 1.0 M in THF), methanol and poly (D, Llactide-co-glycolide; lactide:glycolide (75:25), mol wt 66,000-107,000) (PLGA) were
purchased from Sigma-Aldrich (St. Louis, MO). Distearoyl-phosphatidylethanolaminemethyl-polyethylene glycol conjugate-2000 (DSPE-mPEG2k), 1, 2-distearoyl-sn-glycero-3phosphocholine (DSPC) and 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) were
purchased from Corden Pharma (Cambridge, MA). Flash chromatography was performed
using flash silica gel (32-63 μ) from SiliCycle Inc. (Quebec, Canada). Chemical reactions
were analyzed by thin layer chromatography (T.L.C) on precoated silica plates (200 μm,
F-254) from Sorbtech technologies Inc. (Norcross, GA). The compounds were visualized
by UV fluorescence.
2.5.2 Synthesis and chemicophysical characterization of ABC ProTide
All chemical synthesis reactions were performed under a dry argon atmosphere unless
otherwise noted. ABC ProTide AlaMe was synthezied as previously reported3. Briefly, Lalanine methyl ester (1 mol equiv) and phenyl dichlorophosphate (1 mol equiv) were
suspended in anhydrous CH2Cl2 (15 mL) and cooled to -78°C in a dry ice/ acetone bath.
To this mixture, a pre-cooled (-78°C) solution of anhydrous trimethylamine (2 mol equiv)
in CH2Cl2 was added drop-wise, and the resultant solution was stirred and gradually
warmed to room temperature over 32 h under an inert argon atmosphere. The reaction
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mixture was concentrated on a rotary evaporator to yield a white/yellow solid that was
suspended into diethyl ether and filtered. The filtrate was concentrated to give aryl
aminoacyl phosphochloridate that was used in the next coupling step without further
purification. ABC (1 mol equiv) was dried by azeotroping from anhydrous pyridine, then
suspended in anhydrous THF and cooled to -78 °C under an argon atmosphere. tertBuMgCl (2 mol equiv, 1.0 M solution in THF) was added drop wise to the ABC suspension
and the reaction mixture allowed to stir for an additional 10 min with cooling. A solution of
aminoacyl phosphorochloridate (1.5 mol equiv) in THF was then added dropwise and the
resulting mixture was gradually warmed to room temperature and stirred for 48-90 h. The
reaction mixture was then cooled to 0 °C, quenched with aqueous saturated ammonium
chloride solution or methanol, concentrated, and the desired ABC ProTides isolated by
flash column chromatography on silica gel eluting with 95%-90% CH2Cl2/CH3OH mobile
phase.
NMR spectra were recorded on a Bruker Avance-III HD (Billerica, MA) operating at
500 MHz, a magnetic field strength of 11.7T. Proton NMR data is reported in ppm
downfield from TMS as an internal standard. FT-IR spectra were recorded on a PerkinElmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a UATRaccessary (Perkin-Elmer, Inc., Waltham, MA, USA). Mass spectra were obtained on a
Waters Xevo TQ-S micro triple quadrupole mass spectrometer (Waters, Milford, MA, USA).
Prodrug quantitation was performed on a Waters Breeze HPLC system (Waters, Milford,
MA, USA) using a Kinetex 5 µ C18 100A Phenomenex column. For AlaMe, the mobile
phase consisted of 10 mM potassium phosphate monobasic buffer solution (10 mM
KH2PO4) and acetonitrile (ACN) with a ratio of 65/35, v/v was at a flow rate of 1 mL/min.
The retention time was 3.8 min.
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2.5.3 Cell model for in vitro studies
Human peripheral blood monocytes were obtained and cultured as previously
described7. Briefly, human peripheral blood monocytes were obtained by leukapheresis
from HIV-1/2 and hepatitis B seronegative donors, followed by purification via
countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent
cells in Dulbecco’s mimimum essential medium (DMEM) supplemented with 10% heatinactivated pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000
U/mL recombinant macrophage colony stimulating factor. Cells were maintained at 37 °C
in a 5% CO2 incubator. Seven days later, differentiated macrophages (MDM) were used
for the experiments.
2.5.4 Antiretroviral activity of ABC and AlaMe
The antiviral activities of native ABC and AlaMe against HIV-1ADA were determined in
MDM as previously described8. MDM were incubated with various concentrations of ABC
or AlaMe for 60 min followed by infection with HIV-1ADA at a multiplicity of infection (MOI)
of 0.01 for 4 h. The MDM were washed extensively with phosphate buffered saline (PBS)
to remove excess virus particles. The cells were incubated an additional 10 days in the
presence of the same concentration of drug used before infection. Cell culture medium
was changed every other day with replacement of equivalent drug containing media. At
day 10 post infection, supernatants were collected and analyzed for HIV-1 reverse
transcriptase (RT) activity 9.
2.5.5 Preparation and characterization of NAlaMe
NAlaMe were prepared using a modified thin film hydration technique as described
previously10. Briefly, a mixture of lipids consisting of DSPC, DSPE-PEG2k and DSPG in
10:5:1 weight ratio was coated over drug loaded PLGA nanoparticles to enable sustained
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release of the loaded cargo. Lipids were dissolved in chloroform first and the organic
solvent was carefully removed under vacuum to make sure a thin lipid film was form in a
round-bottom flask. Then lipids were dispersed in 10 mM phosphate buffer (PB) to form
the aqueous phase. PLGA and AlaMe were dissolved in DCM to form the oil phase. A
2:1:1 weight ratio of PLGA to drug to lipid shell was used. The oil phase was added into
the water phase dropwise under gentle stirring. The mixture was vortexed then sonicated
by probe ultrasonicator under ice bath. DCM then was evaporated and the suspension
was centrifuged at 14,000 rpm for 10 min at 4℃ to collect the nanoparticle. Effective
diameter (Deff), PdI, and ζ-potential were measured by dynamic light scattering (DLS)
(Malvern Zetasizer Nano Series Nano-ZS, Malvern Instruments, Westborough, MA,
USA). TEM were used to observe the morphology of NAlaMe.
2.5.6 Cytotoxicity of ABC, AlaMe and NAlaMe
A CCK-8 Kit was purchased from Dojindo and used to test cell viability after treatment
with ABC, AlaMe and NAlaMe. Briefly, MDM plated in a 96-well plate were treated with
100 μl of 0-400 µM ABC, AlaMe and NAlaMe for 24 h. Drug containing medium was
removed and replaced with fresh medium. Ten μl of CCK-8 solution was added to each
well followed by incubation of the plate for 2 h at 37˚C. The absorbance (at 450 nm) of
each well was measured using a microplate reader. The cell viability was calculated
according to manufacturer’s instructions.
2.5.7 Cell uptake and retention of AlaMe and NAlaMe
Uptake and retention of nanoformulations were determined in MDM as previously
reported8,11-14. Briefly, MDM were treated with different nanoformulations at a
concentration of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were
collected in 1 mL PBS after washing with 1 mL PBS twice. MDM were pelleted by
centrifugation at 3,000 rpm for 8 min. The cell pellet was reconstituted in 200 µl methanol
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and probe sonication (10 sec) was used to break the cells and extract drugs. After probe
sonication, cell debris was pelleted by centrifugation at 14,000 rpm for 10 min and 4˚C.
The supernatant was analyzed for prodrug level using HPLC-UV/Vis. For retention, MDM
were treated with 100 µM different nanoformulations for 8 h. The nanoformulationcontaining media were replaced with fresh media after washing MDM with PBS twice. At
days 1, 5, 10, and 15, MDM were collected in 1mL PBS after washing with 1 mL PBS
twice. The samples were processed as described above for analysis using HPLC.
2.5.8 Antiretroviral efficacy
Antiretroviral efficacies of ABC, AlaMe and NAlaMe in MDM were assessed as
previously described8. MDM were incubated with 100 µM different treatment for 8 h. Then
drug-containing medium was replaced with fresh medium after washing MDM with PBS
twice. Half media changes were conducted every other day. At predetermined time points,
day 1, 5 ,10, and 15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured
with every-other-day half media changes for an additional 10 days. At day 10, supernatant
was collected for RT assay and MDM were fixed with paraformaldehyde and
immunostained for expression of HIVp24. Untreated, uninfected MDM served as negative
(control), while MDM exposed to HIV-1ADA but not treated with drugs, served as positive
controls (HIV-1).
2.5.9 Pharmacokinetic study of ABC and NAlaMe
Male BALB/cJ mice (Jackson Labs, Bar Harbor, ME, USA) were administrated
subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC equivalent dose. At 2h, day 1, 3
and 7, three mice from each group were sacrificed, and blood, spleen and lymph nodes
(pooled) were collected as previously reported before. Specifically, bloods were collected
in EDTA tubes and PBMCs were separated using Histopaque-1083 (Sigma Chemical Co.
St. Louis, MO; Catalog # 1083-1) according to the manufacturer’s instruction. Separated
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PBMCs were centrifuged (400 g for 10 min), resuspended in 200 μl of 70% methanol and
stored in −20 °C until sample preparation for CBV-TP measurement. Spleens were
collected, minced into small pieces using scalpel blades, and transferred to 70 μm nylon
cell strainers (BD Falcon # 352350) inserted into the top of 50-ml conical tubes. 5 ml of
HBSS was added in total and single cells were forced to pass through strainers. Cell were
pelleted by centrifugation at 200g for 10 min, and supernatants were discarded. The
resulting cell pellets were resuspended in one ml of RBC lysing buffer (ACK buffer),
incubated for two minutes at 37 °C, neutralized with 14 ml of HBSS, centrifuged at 200g
for 10 min, supernatants were discarded, and cell pellets underwent one more cycle of
washing and centrifugation. The resulting cell pellet was resuspended in 2 ml PBS and
counted with a hemocytometer. Finally, cells were centrifuged at 400 g for 10 min and cell
pellet was lysed with 200 μl of cold 70% MeOH for CBV-TP sample extraction. For lymph
node lymphocyte preparation, freshly removed lymph nodes from all three mice were
pooled (∼15–18 lymph nodes) for every time-point, and cells were isolated similarly to
splenocytes as described above, except that the RBC lysis step was not used.
2.5.10 Pharmacodynamics study of ABC and NAlaMe
Male 6-8-week-old NOD/scid-IL-2Rγcnull (NSG) mice (Jackson Labs, Bar Harbor, ME,
USA) were reconstituted by intraperitoneal injection with 25 × 106 human peripheral blood
lymphocytes (PBL) obtained by leukapheresis and centrifugal elutriation. 10 days after
reconstitution, mice were injected subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC
equivalent dose. 11 days after reconstitution, mice were challenged with 104 50% tissue
culture infectious dose (TCID50) HIV-1ADA by intraperitoneal (IP) injections. Mice were
sacrificed 10 days after viral challenge. Blood were collected 1 day before and 10 days
after viral challenge for flow cytometry analysis of human pan-CD45, CD3, CD4 and CD8
immune markers15. Tissues were also collected at the sacrifice day for viral RNA and DNA
34

quantitation by semi-nested real-time PCR16, and immunohistochemical staining for HIV1p24 antigen as described previously17.
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Figure 2.1 Synthesis scheme of AlaMe.
Reagent and condition: a. Phenyl dichlorophosphate, Et3N, CH2Cl2, -78 ℃-rt, 16 h.
b. ABC, tert-BuMgCl, THF, -78 - rt, 48-90 h.
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Figure 2.2 EC50 of ABC and AlaMe in MDM against HIV-1ADA.
MDM were incubated with various concentrations of ABC or AlaMe for 60 min followed
by infection with HIV-1ADA at a multiplicity of infection (MOI) of 0.01 for 4 hr. The MDM
were washed extensively with phosphate buffered saline (PBS) to remove excess virus
particles. The cells were incubated an additional 10 days in the presence of the same
concentration of drug used before infection. Cell culture medium was changed every other
day with replacement of equivalent drug containing media. At day 10 post infection,
supernatants were collected and analyzed for HIV-1 reverse transcriptase (RT) activity 9.
The EC50 of ABC or AlaMe is 161.7 or 23.9 nM, respectively.
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Figure 2.3 Preparation and characterization of NAlaMe.
A. Scheme of NAlaMe preparation. Briefly, a mixture of lipids consisting of DSPC,
DSPE-PEG2k and DSPG in 10:5:1 weight ratio was coated over drug loaded PLGA
nanoparticles to enable sustained release of the loaded cargo. Lipids were dissolved in
chloroform first and the organic solvent was carefully removed under vacuum to make
sure a thin lipid film was form in a round-bottom flask. Then lipids were dispersed in 10
mM phosphate buffer (PB) to form the aqueous phase. PLGA and AlaMe were dissolved
in DCM to form the oil phase. A 2:1:1 weight ratio of PLGA to drug to lipid shell was used.
The oil phase was added into the water phase dropwise under gentle stirring. The mixture
was vortexed then sonicated by probe ultrasonicator under ice bath. DCM then was
evaporated, and the suspension was centrifuged at 14,000 rpm for 10 min at 4℃ to collect
the nanoparticle. B. TEM image of NAlaMe.
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Figure 2.4 Cytotoxicity of ABC, AlaMe and NAlaMe.
MDM plated in a 96-well plate were treated with 100 μl of 0-400 µM ABC, AlaMe and
LNAlaMe for 24 hr. Drug containing medium was removed and replaced with fresh
medium. Ten μl of CCK-8 solution was added to each well followed by incubation of the
plate for 2 hr at 37˚C. The absorbance (at 450 nm) of each well was measured using a
microplate reader. The cell viability was calculated according to manufacturer’s
instructions.
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Figure 2.5 Cell uptake and retention of AlaMe and NAlaMe in MDM.
A. Uptake study. MDM were treated with different nanoformulations at a
concentration of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were
collected in 1 mL PBS, pelleted by centrifugation at 3,000 rpm for 8 min. The cell pellet
was reconstituted in 200 µl methanol and analyzed by HPLC. B. Retention study, MDM
were treated with 100 µM different nanoformulations for 8 h. The nanoformulationcontaining media were replaced with fresh media after washing MDM with PBS twice. At
days 1, 5, 10, and 15, MDM were collected in 1mL PBS after washing with 1 mL PBS
twice. The samples were processed as described above for analysis using HPLC.
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Figure 2.6 p24 staining of MDM for antiretroviral study.
MDM were incubated with 100 µM different treatment for 8 h. Then drug-containing
medium was replaced with fresh medium after washing MDM with PBS twice. Half media
changes were conducted every other day. At predetermined time points, day 1, 5 ,10, and
15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured with every-otherday half media changes for an additional 10 days. At day 10 after infection, MDM were
fixed with paraformaldehyde and immunostained for expression of HIVp24. Untreated,
uninfected MDM served as negative control (control), while MDM exposed to HIV-1ADA but
not treated with drugs, served as positive controls (HIV-1).
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Figure 2.7 RT assay result of MDM for antiretroviral study.
MDM were incubated with 100 µM different treatment for 8 h. Then drug-containing
medium was replaced with fresh medium after washing MDM with PBS twice. Half media
changes were conducted every other day. At predetermined time points, day 1, 5 ,10, and
15, MDM were infected with HIV-1ADA for 4 h at a MOI of 0.1 and cultured with every-otherday half media changes for an additional 10 days. At day 10 after infection, media were
collected for RT assay. Untreated, uninfected MDM served as negative control (control),
while MDM exposed to HIV-1ADA but not treated with drugs, served as positive controls
(HIV-1).
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Figure 2.8 Pharmacokinetic results of ABC and NAlaMe.
CBV-TP level in PBMC separated from blood samples (A), and cells separated
from spleen (B) and lymph nodes (C). Male BALB/cJ mice were injected
subcutaneously with ABC or NAlaMe at 54.3 mg/kg ABC equivalent dose. At 2 h, day 1,
3 and 7, three mice from each group were sacrificed, and blood, spleen and lymph nodes
(pooled) were collected. PBMC or cells are separated from blood, spleen and lymph nodes.
CBV-TP levels were extracted and analyzed by LC-MS.
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Figure 2.9 Comparison of antiretroviral activities of ABC and NAlaMe in hu-PBL
reconstituted NSG mice infected with HIV-1.
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Male NOD/scid-IL-2Rγcnull (NSG) mice were reconstituted by IP injection with 25 × 106
human peripheral blood lymphocytes (PBL) obtained by leukapheresis and centrifugal
elutriation. 10 days after reconstitution, mice were injected subcutaneously with ABC or
NAlaMe at 54.3 mg/ka ABC equivalent dose. 11 days after reconstitution, mice were
challenged with 104 50% tissue culture infectious dose (TCID50) HIV-1ADA by IP injections.
Mice were sacrificed 10 days after viral challenge. Blood were collected 1 day before and
10 days after viral challenge for flow cytometry analysis of human pan-CD45, CD3, CD4
and CD8 immune markers (A). Tissues were collected at the sacrifice day for viral RNA
and DNA quantitation by semi-nested real-time PCR (B-F).
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Figure 2.10 Levels of HIV-1p24 antigen in liver and spleen of HIV-1 infected
huPBL-reconstituted NSG mice treated with ABC and NAlaMe.
Spleens were collected on sacrifice day, then sectioned and immunostained with
antibodies specific for HLA-DR or HIV-1p24 and visualized by DAB.
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Chapter 3
Creation of a Nanoformulated ABC ProTide LA
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3.1 Abstract
The entry of LA formulation into clinical practice can broaden current available
therapeutic approaches for treatment of HIV infection. LA serves to facilitate ARV HIV
reservoir delivery while improving patient adherence and reducing viral resistance and
drug toxicity. In works to develop a library of LA formulations, ABC, a NRTIs and a
component of a first line HIV treatment was modified by ProTide technology to increase
its potency. Three ABC ProTides (AlaMe, PheMe and PheC22) were synthesized. The
hydrophobicity produced by a fatty alcohol moiety of PheC22 further enhanced its
apparent half-life. A single treatment of human monocyte derived macrophages with
PheC22 nanoformulations led to sustained intracellular carbovir-triphosphate (CBV-TP)
and potent antiretroviral activity for up to 30 days.
3.2 Introduction
The translation of LA formulation from laboratory research into clinical practice could
improve HIV prevention and treatment and inevitably speed viral eradication efforts. The
advantages of LA formulation over other antiretroviral regimens are defined by high ARV
penetrance into cell and tissue viral reservoirs and infrequent dosing requirements. Both
affect treatment outcomes by maximally suppressing viral growth through facilitated ARV
entry into viral target cells1,2. Regimen adherence can be improved by reducing the dosing
frequency. But only a few FDA approved ARVs have the right properties for LA formulation.
The development of LASER ART technology that can modify the chemical, physical and
biological properties of ARVs allowed LA formulation to be developed for more ARVs.
Indeed, recent data from our laboratories demonstrate that conversion of existing ARVs
into prodrugs extend their apparent half-lives and reduce systemic drug toxicities3-6.
However, while prodrugs represent > 10% of all small molecules approved for human use,
few entered into HIV treatment regimens and none have appeared as part of long-acting
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ARV therapies7. Nonetheless, their advantages in facilitating drug biodistribution and
extending drug half-lives is already known8.
Herein，ABC ProTide LA were successfully developed by ProTide technology. While
the idea was first introduced more than two and a half decades ago, the application of
ProTide technology to ABC has focused on improving drug potency9,10 not in extending its
apparent half-life or in affecting viral reservoir biodistribution. To these ends, we
implemented strategies to mask parent drug monophosphates with cleavable hydrophobic
lipid creating ProTides that demonstrated improved plasma drug stability, membrane
penetration and encapsulation. The synthesis and antiretroviral profiles of three ABC
ProTides are described. One, PheC22 was defined by efficient encasement into
nanoparticles, production of high intracellular CBV-TP metabolites and superior
monocyte-macrophage depot formation that enhanced antiretroviral activities.
3.3 Results
3.3.1 Synthesis of ABC ProTides
Prior

works

demonstrated

that

L–alanine

and

L-phenylalanine

ester

phosphoramidates provide potent ProTides10,11. Thus, we created AlaMe and PheMe
bearing alanine and phenylalanine methyl ester residues. PheC22 was synthesized by
substituting the methyl ester in PheMe for a docosyl ester promoiety. A docosanol masking
ester motif was selected based on its lipophilicity, antiviral activities and inherent
synergistic effect on nucleoside analogs12,13. ProTide hydrolysis was reasoned to release
two pharmacophores that inhibit viral reverse transcriptase activity14. We reasoned that
improving ABC physicochemical features would facilitate nanoformulation preparation,
enhance intracellular ABC levels and extend the drugs’ apparent half-life. The first step in
the

synthesis

of

ABC

ProTides

required
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preparation

of

aryl

amino

ester

phosphorochloridates from appropriate amino acid esters and commercially available
phenyl phosphorodichloridate15. Phenylalanine and alanine methyl esters were purchased
while phenylalanine docosyl ester was prepared according to step 1 of Figure 3.1. The
aryl amino ester phosphorochloridates were then synthesized by coupling phenyl
phosphorodichloridates to amino acid esters in the presence of triethylamine (Figure 3.1
Step 2)10. Each of the amino ester phosphorochloridate was then reacted with ABC in the
presence of tert-BuMgCl and purified by flash column chromatography. This generated
high yields of AlaMe, PheMe and PheC22. Successful synthesis of ABC ProTides was
confirmed by 1H,

13

C and
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P NMR spectra (Figure 3.2-3.5). As previously reported for

similar compounds, splitting of peaks in the spectra of ProTides was associated with coexistence of two stereoisomers at the phosphorus atom16.
3.3.2 Antiretroviral activity of ABC ProTides
We next evaluated the ProTides for antiretroviral activity. As shown in (Figure 3.6B),
AlaMe, PheMe and PheC22 exhibited 6- to 200- fold increase in antiretroviral activity over
ABC in human monocyte-derived macrophages (MDM). PheMe demonstrated the lowest
EC50 of 0.2 nM. The EC50 of AlaMe and PheC22 were 1.8 nM and 7.0 nM, respectively.
The differences were likely linked to higher prodrug uptake and metabolism of PheMe to
form CBV-TP in MDM17. Activation of ABC ProTides require intracellular processing to
generate CBV-TP10. To better explain the differences in EC50 between native ProTides
and ABC, MDM were exposed to equivalent concentrations of ABC, AlaMe, PheMe or
PheC22 followed by quantitation of CBV-TP levels at multiple time points. As shown in
Figure 3.6C, maximum CBV-TP levels for ABC, AlaMe, PheMe and PheC22 were 177,
35650, 33135 and 541 fmol/million cells, respectively. At 48 h, CBV-TP levels were 33,
789, 5025 and 230 fmol/million cells for ABC, AlaMe, PheMe and PheC22. The differences
in active metabolite levels further suggest that the three ProTides are rapidly taken up by
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MDM but metabolized at rates dependent on amino acid ester hydrolysis. Notably, at 48
h, CBV-TP levels for PheC22 declined only by 57% compared to 81, 97 and 84% in the
amount of active metabolite for ABC, AlaMe and PheMe. We posit that enhanced
lipophilicity and slower hydrolysis of PheC22 provides controlled and extended release of
CBV-TP.
3.3.3 Cytotoxicity of ABC ProTides.
As intracellular nucleoside triphosphate levels have been implicated in drug toxicities18,
we assessed mitochondrial dehydrogenase activity of the ProTides using CCK-8 assay.
As shown in Figure 3.6D, neither ABC, AlaMe, PheMe nor PheC22 affected cell viability
at drug concentrations of up to 300 µM. However, differences in mitochondrial activity
were seen at 400 µM with AlaMe and PheMe compared to ABC. No significant differences
were observed between PheC22 and ABC across all tested drug concentrations. These
data indicated that the sustained release of effective inhibitory concentration of CBV-TP
from PheC22 was not detrimental to cell viability and suggested that PheC22 could be
translated for human use. Previous studies have shown that in vivo accumulation of
nucleoside triphosphates inside cells could be facilitated by prodrugs that exhibit greater
stability in plasma19,20.
3.3.4 Serum stability of ABC ProTides
To evaluate prodrug stability, we incubated three ProTides in human serum. After 24
h, > 60% of AlaMe and PheMe were hydrolyzed. Nineteen percent of PheC22, in contrast,
was degraded after 24 h.
3.3.5 Preparation and characterization of nanoformulations for ABC ProTides.
LASER ART was developed, in our laboratories, to improve therapeutic and
prophylactic outcomes for HIV/AIDS. In the first phase this was accomplished by
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formulating myristoylated prodrugs encased in a poloxamer surfactant3-6. For ABC, such
modifications provided only low levels of CBV-TP for less than two weeks5,21. We reasoned
that ABC ProTide nanoformulations would produce higher levels of intracellular CBV-TP
at substantially reduced dosing frequency. The less hydrophobic AlaMe was encapsulated
into lipid-coated poly lactic-co-glycolic acid (PLGA) nanoparticles (NAlaMe) by a modified
single emulsion solvent evaporation method while hydrophobic and lipophilic PheMe and
PheC22 ProTides were stabilized into poloxamer coated drug nanoparticles (NPheMe and
NPheC22) by high-pressure homogenization22-24. The directive of both schemes was to
produce controlled release drug delivery systems. Drug loading for NAlaMe, NPheMe and
NPheC22 nanoparticles were 3, 43, and 47%, respectively, underlying the differences
between PLGA and poloxamer drug encasement systems. Indeed, unlike high-pressure
homogenization that produces nanoparticles stabilized by surfactants with high drug
loading, PLGA nanoparticles exhibit low drug loading22,25. Effective diameter (Deff), PdI,
and ζ-potential were determined by dynamic light scattering (DLS) (Table 3.1) while
transmission electron microscopy (TEM) assessed nanoparticle morphologies (Figure
3.7). Nanoparticle morphologies for NAlaMe and NPheC22were spherical with particle
sizes of 135 nm and 230 nm, respectively, while NPheMe particles were rod-shaped with
a size of 265 nm. Importantly, high drug loading in NPheMe and NPheC22
nanoformulations can translate into reduced dosage volumes and minimal injection site
reactions24.
3.3.6 Uptake and retention study in MDM for nanoformulated ABC ProTides
LASER

ART

has

been

shown

to

improve

ART

pharmacokinetics

and

pharmacodynamics by facilitating cell and tissue drug depots in the reticuloendothelial
system26-28. Macrophages are outstanding targets for LASER ART due to their large
storage capacity, high mobility that allows entry to sites of infection and inflammation, and
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their role as viral reservoirs29,30. To affirm such observations, NAlaMe, NPheMe and
NPheC22 were administered to MDM at concentrations of 100 μM. Intracellular prodrug
concentrations were subsequently evaluated over 8 h. As shown in Figure 3.8A, the
highest drug nanoparticle MDM uptake was observed with NPheC22. At 8 h, intracellular
prodrug concentration for NPheC22 was 118.5 nmol/106 cells, a 56- and 108-fold higher
concentration than that observed for NAlaMe (2.1 nmol/106 cells) or NPheMe (1.1
nmol/106 cells), respectively. Visualization of nanoparticles within MDM by TEM revealed
greater accumulation of NPheC22 nanoparticles in the cytoplasmic vesicles compared to
NAlaMe and NPheMe (Figure 3.8E). These observations likely reflect nanoparticle
stability31,32. To further confirm release of ProTides from nanoparticles and conversion to
active metabolites, we quantified intracellular CBV-TP levels in MDM after a single
exposure of ABC, NAlaMe, NPheMe or NPheC22. As shown in Figure 3.8B, CBV-TP
levels for ABC increased over time and peaked at 4 h (811 fmol/106 cells) before declining
by 37% (510 fmol/106 cells) at 8 h. For NAlaMe, maximum CBV-TP levels were observed
at 8 h (39,533 fmol/106 cells) while NPheMe displayed the highest CBV-TP concentration
of 39,015 fmol/106 cells at 4 h followed by a 43% decrease (22,274 fmol/106 cells) at 8 h.
Even though lower concentrations of CBV-TP were measured for NPheC22 compared to
NAlaMe or NPheMe, the active metabolite levels were sustained over 8 h, ranging from
4,626 to 8,601 fmol/106 cells versus 215 and 811 fmol/106 cells for ABC. Conversion of
PheC22 to CBV-TP demonstrates sustained drug release and could lead to improved
patient adherence to therapeutic ARVs33-35. Studies amongst HIV-1 infected patients have
revealed preferences for long acting ART36. To explore the potential of ProTide
formulations to extend ABC apparent half-life, MDM were exposed to formulations for 8 h.
Intracellular ProTide and CBV-TP levels were measured over a 30-day time period. As
shown in Figure 3.8C, the amount of ProTide retained by MDM was not detected for
NAlaMe and NPheMe, while NPheC22 exhibited drug concentrations of 95.3 and 48.5
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nmol/106 cells at days 1 and 30. The retention of CBV-TP in MDM (Figure 3.8D) was
sustained until day 30 for NAlaMe, NPheMe and NPheC22 but only detected to day 5 for
ABC. Notably, a single treatment of MDM with NPheC22 provided steady and sustained
CBV-TP levels greater than 100 fmol/106 cells over the entire 30-day period. Such
sustained release formulations could minimize variant pharmacokinetic profiles and
maintain effective drug concentrations at cellular and tissue reservoirs of infection.
3.3.7 In vitro antiretroviral efficacy of nanoformulated ABC ProTides
To determine whether sustained intracellular CBV-TP from ProTide formulations
would translate into improved antiretroviral activity, MDM were challenged with HIV-1ADA
for up to 30 days after a single 8 h treatment with 100 µM of ABC equivalent. HIV-1 reverse
transcriptase (RT) activity and p24 antigen expression were assessed in infectious
supernatants and adherent MDM on day 10 post-infection. As shown in Figure 3.9A and
3.9C, complete viral inhibition was observed for up to 15 days for NAlaMe. At day 20, 91%
viral inhibition was recorded that gradually decreased to 83% inhibition at day 30. HIV1p24 antigen staining showed that NPheMe protected MDM from infection with viral
breakthrough at day 30. Of significance, full viral inhibition was observed for 30 days after
treatment with NPheC22. In contrast, minimal protection against viral infection was
observed with native ABC at all time points. Comparisons of antiviral efficacy of NPheC22
were then assessed to determine the lowest drug concentration required for long-term
MDM protection against viral infection. As shown in Figure 3.9B and 3.9D, 50 µM
NPheC22 afforded complete viral inhibition for up to 30 days, while a single 8 h treatment
with 25 µM or 10 µM NPheC22 inhibited viral replication by greater than 90% at day 30
post drug treatment. These results paralleled prolonged high intracellular CBV-TP levels
for NPheC22 compared to ABC, NAlaMe or NPheMe.
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3.3.8 Pilot pharmacokinetic study.
A pilot in vivo study in rats was conducted with NPheC22. Peripheral blood
mononuclear cells were recovered from whole blood and intracellular CBV-TP levels
measured up to day 7. Reduced CBV-TP levels might be explained, in part, by the rapid
degradation of ProTides or slow cleavage of phosphoramide intermediates in rodents that
precedes triphosphate formation 37,38.
3.4 Discussion
We posit that LA formulation can overcome challenges of ARV adherence and
biodistribution. In support of this idea, AlaMe, PheMe and PheC22 ProTides were
synthesized. NPheC22 nanoparticles exhibited improved MDM drug uptake, sustained
retention and antiretroviral activities for up to one month. We posit that this work is a
significant step forward for the management and prevention of HIV-1 infection.
3.5 Methods
3.5.1 Reagents
All chemical synthesis reactions were performed under a dry argon atmosphere unless
otherwise noted. Reagents were obtained from commercial sources and used directly;
exceptions are noted. Abacavir (ABC) was purchased from BOC Sciences Inc. (Shirley,
NY). Phenyl dichlorophosphate, L-alanine methyl ester hydrochloride salt, Lphenylalanine methyl ester hydrochloride salt, N-(carbobenzyloxy)-L-phenylaline,
docosanol, dichloromethane (CH2Cl2), chloroform (CHCl3), N,N-dimethylformamide (DMF),
triethylamine (Et3N), diethyl ether, tetrahydrofuran (THF), tert-Butylmagnesium chloride
solution (tert-BuMgCl, 1.0M in THF), triethylsilane (Et SiH), methanol and poly (D, L3

lactide-co-glycolide; lactide:glycolide (75:25), mol wt 66,000-107,000) (PLGA) were
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purchased from Sigma-Aldrich (St. Louis, MO). Distearoyl-phosphatidylethanolaminemethyl-polyethylene glycol conjugate-2000 (DSPE-mPEG2k), 1, 2-distearoyl-sn-glycero-3phosphocholine (DSPC) and 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) were
purchased from Corden Pharma (Cambridge, MA). 1-[Bis(dimethylamino)methylene]-1H1,2,3-triazolo[4,5-b] pyridinium 3-oxid hexafluorophosphate (HATU) was obtained from
Bachem Inc. (Torrance, CA) while palladium, 10% on activated carbon, was purchased
from STREM Inc. (Newburyport, MA). Flash chromatography was performed using flash
silica gel (32-63 μ) from SiliCycle Inc. (Quebec, Canada). Chemical reactions were
analyzed by thin layer chromatography (T.L.C) on precoated silica plates (200 μm, F-254)
from Sorbtech technologies Inc. (Norcross, GA). The compounds were visualized by UV
fluorescence or by staining with ninhydrin or KMnO4 reagents.
3.5.2 General Methods
High performance liquid chromatograph (HPLC): Prodrug quantitation was performed
on a Waters Breeze HPLC system (Waters, Milford, MA, USA) using a Kinetex 5 µ C18
100A Phenomenex column. HPLC grade acetonitrile and methanol were purchased from
Fisher Chemical. For all three ProTide samples, 10 mM potassium phosphate monobasic
buffer solution (10 mM KH2PO4) was used at a flow rate of 1 mL/min. Specifically, AlaMe
was eluted in 10 mM KH2PO4/acetonitrile (65/35, v/v) mobile phase with a retention time
of 3.8 min; PheMe had a retention time of 4.2 min in 10 mM KH2PO4/acetonitrile (55/45,
v/v), while PheC22 had a retention time of 7.0 min in 10 mM KH2PO4/methanol (2/98, v/v).
Nuclear Magnetic Resonance (NMR): NMR spectra were recorded on a Bruker
Avance-III HD (Billerica, MA) operating at 500 MHz, a magnetic field strength of 11.7T.
Proton NMR data is reported in ppm downfield from TMS as an internal standard.
Mass Spectrometry (MS): Mass spectra were obtained on a Waters Xevo TQ-S micro
triple quadrupole mass spectrometer (Waters, Milford, MA, USA).
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Fourier-transform infrared spectroscopy (FTIR): FTIR spectra were recorded on a
Perkin-Elmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a UATRaccessary (Perkin-Elmer, Inc., Waltham, MA, USA).
3.5.3 Synthesis and characterization
Z-Phe-Odoc (2): Triethylamine (1.35 g, 1.86 mL, 13.36 mmol, 2.0 equiv.), imidazole
(454 mg, 6.68 mmol, 1.0 equiv.) and HATU (3.81 g, 10.02 mmol, 1.5 equiv.) were added
to a solution of Z-Phe-OH (2 g, 6.68 mmol, 1.0 equiv.) and docosanol (2.4 g, 7.35 mmol,
1.1 equiv.) in a mixture of CHCl3 (25 mL) and DMF (25 mL) at 0 ºC under an argon
atmosphere. The mixture was then heated at 45 °C for 48 h and concentrated. The crude
product was diluted with CH2Cl2 (100 mL), washed successively with 1 M HCl, saturated
NaHCO3 and brine (80 mL each). The organic extract was dried over Na2SO4 and
concentrated. The residue was purified by flash chromatography eluting with 4:1
Hex/EtOAc to give Z-Phe-Odoc (3.46 g, 85 %) as a colorless solid. 1H NMR (500 MHz,
CD3OD): 7.24-7.42 (m, 9H), 7.13 (d, J = 6.7 Hz, 2H), 5.25 (d, J = 4.0 Hz, 1H), 5.07-5.17
(m, 1H), 4.68 (dd, J = 13.6, 6.0 Hz 1H), 4.12 (td, J = 13.6, 6.7 Hz 2H), 3.14 (m, 2H), 1.60
(br, 2H), 1.29 (br, 38H), 0.92 (t, J = 6.9 Hz 3H).

13

C NMR (125 MHz, CDCl3): δ 171.6,

155.6, 136.2, 135.7, 129.2, 128.5, 128.4, 29.2, 28.4, 25.8, 22.7, 14.1. MS-ES+ (m/z):
calcd. for C39H61NO4, 607.46 (100%), 608.46 (42.2%), 609.47 (8.7%); found, 608.46
[M+H+].
H-Phe-Odoc (3c): To a solution of 2 (3.46 g, 5.695 mmol, 1.0 equiv.) in mixture of
anhydrous MeOH (20 mL) and CHCl3 (10 mL) was added Pd/C (1.4g, 40% wt). The
reaction mixture was cooled to 0°C followed by drop wise addition of triethylsilane39 (6.6
g, 9.1 mL, 59.95 mmol, 10.0 equiv.). The reaction mixture was then stirred under an
atmosphere of argon at room temperature for 16 h, filtered through Celite TM ® and then
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concentrated to give H-Phe-Odoc (quantitative yield), that was precipitated from ether and
used in the next step without further purification.
General Procedure A: Aryl aminoacyl phosphorochloridates10
The amino acid ester (1 mol equiv) and phenyl dichlorophosphate (1 mol equiv) were
suspended in anhydrous CH2Cl2 (15 mL) and cooled to -78°C in a dry ice/ acetone bath.
To this mixture, a pre-cooled (-78°C) solution of anhydrous trimethylamine (2 mol equiv)
in CH2Cl2 was added drop-wise, and the resultant solution was stirred and gradually
warmed to room temperature over 32 h under an inert argon atmosphere. The reaction
mixture was concentrated on a rotary evaporator to yield a white solid that was suspended
into diethyl ether and filtered. The filtrate was concentrated to give aryl aminoacyl
phosphochloridates that were used in the next coupling step without further purification.
General Procedure B: Abacavir ProTides10
ABC (1 mol equiv) was dried by azeotroping from anhydrous pyridine, then suspended
in anhydrous THF and cooled to -78 °C under an argon atmosphere. tert-BuMgCl (2 mol
equiv, 1.0 M solution in THF) was added drop wise to the ABC suspension and the reaction
mixture allowed to stir for an additional 10 min with cooling. A solution of aminoacyl
phosphorochloridate (1.5 mol equiv) in THF was then added drop-wise and the resulting
mixture was gradually warmed to room temperature and stirred for 48-90 h. The reaction
mixture was then cooled to 0 °C, quenched with aqueous saturated ammonium chloride
solution or methanol, concentrated, and the desired ABC ProTides isolated by flash
column chromatography on silica gel eluting with 95%-90% CH2Cl2/CH3OH mobile phase.
Preparation of AlaMe (5a). Synthesized according to general procedure B. On a scale
of 1.0 g (3.49 mmol) of ABC, 1.4 g (2.66mmol, 76 % yield) of AlaMe product was formed:
1

H NMR (500 MHz, CD3OD): 7.66 (d, J = 6.6 Hz 1H), 7.10-7.40 (m, 6H), 6.15 (dd, J = 13.7,
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5.7 Hz 1H), 5.97 (br, 1H), 5.53 (br, 1H), 4.08-4.30 (m, 2H), 3.85-4.0 (m, 1H), 3.23 (s, 3H),
3.21 (br, 1H), 2.93 (br, 1H), 2.81 (td, J = 16.9, 8.3 Hz 1H), 1.65-1.80 (m, 1H), 1.20-1.40
(m, 4H), 0.85 (app. d, J = 5.8 Hz 2H), 0.62 (br, 2H). 13C NMR (125 MHz, CDCl3): δ 175.4,
161.7, 157.4, 152.2, 138.1, 137.2, 131.7, 130.6, 126.1, 123.7, 121.4, 114.8, 70.1, 60.5,
52.7, 51.5, 47.1, 35.4, 24.3, 20.8, 20.5, 14.5, 7.6.

31

P NMR (202 MHz, CD3OD); 3.87,

3.58. MS-ES+ (m/z): calcd. for C24H30N7O5P, 527.20 (100%), 528.21 (26.0%), 529.21
(2.7%); found, 528.2 [M+H+].
Preparation of PheMe (5b). Synthesized according to general procedure B. On a
scale of 1.6 g (5.59 mmol) of ABC, 1.9 g (3.15mmol, 55 % yield) of PheMe was formed:
1

H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 7.09-7.40 (m, 10H), 7.06 (d, J = 7.6

Hz 1H), 6.01-6.08 (m, 1H), 5.87-5.95 (m, 1H), 5.43-5.53 (m, 1H), 4.15 (dd, J = 14.8, 9.1
Hz 1H), 3.92-4.04 (m, 1H), 3.45-3.80 (m, 5H), 2.88-3.14 (m, 3H), 2.78-2.87 (m, 1H), 2.652.74 (m, 1H), 1.50-1.58 (m, 1H), 0.82-0.89 (m, 2H), 0.57-0.65 (m, 2H).

13

C NMR (125

MHz, CDCl3): δ 174.5, 157.4, 152.2, 152.1, 151.6,138.3, 138.1, 137.2, 131.5, 130.7,
130.6, 129.5, 127.9, 126.0, 125.9, 121.6, 121.1,114.8, 69.8, 69.7, 60.4, 57.9, 57.7, 52.6,
46.8, 40.8, 35.4, 24.4, 7.6.
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P NMR (202 MHz, CD3OD); 3.62, 3.22. MS-ES+ (m/z):

calcd. for C30H34N7O5P, 603.24 (100%), 604.24 (32.4%), 605.24 (2.4%); found, 604.24
[M+H+].
Preparation of PheC22 (5c). Synthesized according to general procedure B. On a
scale of 1.1 g (3.84 mmol) of ABC, 2.4 g (2.64mmol, 68% yield) of PheC22 product was
formed: 1H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 6.95-7.44 (m, 11 H), 6.04 (br,
1H), 5.88-5.95 (m, 1H), 5.48 (br, 1H), 4.13 (d, J = 15.2, 8.7 Hz 1H), 3.89-4.09 (m, 3H),
3.47-3.59 (m, 2H), 2.64-3.15 (m, 5H), 1.45-1.64 (m, 3H), 1.07-1.39 (br, 42H), 0.91 (t, J =
6.6 Hz 3H), 0.84-0.87 (m, 2H), 0.61 (br, 2H). 13C NMR (125 MHz, CD3OD): δ 174.2, 157.4,
154.3, 152.1, 144.9, 138.3, 138.2, 138.0, 137.9, 137.1, 131.5, 130.6, 130.5, 130.3,
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130.1, 129.6, 128.9, 127.9, 126.7, 125.9, 124.1, 121.9, 121.4, 121.3, 121.1, 114.8, 69.9,
66.7, 66.4, 63.2, 60.4, 58.1, 57.8, 46.8, 41.1, 35.4, 33.1, 31.2, 30.7, 30.5, 29.6, 29.5,
26.9, 23.8, 14.5, 7.6; 31P NMR (202 MHz, CD3OD); 3.25, 3.54. MS-ES+ (m/z): calcd. for
C51H76N7O5P, 897.56 (100%), 898.57 (55.2%), 899.57 (14.9%); found, 898.56 [M+H+].
3.5.4 Cell model for in vitro studies.
Human peripheral blood monocytes were obtained and cultured as previously
described40. Briefly, human peripheral blood monocytes were obtained by leukapheresis
from HIV-1/2 and hepatitis B seronegative donors, followed by purification via
countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent
cells in Dulbecco’s mimimum essential medium (DMEM) supplemented with 10% heatinactivated pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000
U/mL recombinant macrophage colony stimulating factor. Cells were maintained at 37 °C
in a 5% CO2 incubator. Seven days later, differentiated macrophages (MDM) were used
for the experiments.
3.5.5 Antiretroviral activity of ABC and its ProTides.
The antiviral activities of native ABC and ABC ProTides against HIV-1ADA were
determined in MDM as previously described5. MDM were incubated with various
concentrations of ABC or ABC ProTides for 60 min followed by infection with HIV-1ADA at
a multiplicity of infection (MOI) of 0.01 for 4 h. The MDM were washed extensively with
phosphate buffered saline (PBS) to remove excess virus particles. The cells were
incubated an additional 10 days in the presence of the same concentration of drug used
before infection. Cell culture medium was changed every other day with replacement of
equivalent drug containing media. At day 10 post infection, supernatants were collected
and analyzed for HIV-1 reverse transcriptase (RT) activity 41.
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3.5.6 Intracellular level of CBV-TP of ABC and its ProTides.
Intracellular levels of CBV-TP were measured as previously described9. MDM were
treated with 10 µM ABC and ABC ProTides. At 3, 6, 12, 24 and 48 h after treatment, MDM
were washed with PBS to remove excess free drug. The cells were then collected in 70%
methanol. CBV-TP from MDM was extracted and quantitated by LC-MS/MS as previously
described21. Sep-Pak QMA cartridges (360 mg, 37-55 µm; Waters) were used to separate
CBV-TP from their mono- and di-phosphates counterparts. The QMA cartridges were
conditioned with 10 ml of 500 mM KCl followed by 10 ml of 5mM KCl. Samples were
loaded onto the cartridges and washed with 15 ml of 75mM KCl. The triphosphate fraction
was eluted with 3 ml of 500 mM KCl and collected for de-phosphorylation. The pH of the
TP fraction was lowered to 4.25 by adding 15 µl ammonium acetate buffer (pH 4,10 mM)
per ml eluate, and dephosphorylated by adding one unit of type XA sweet potato acid
phosphatase per ml eluate and incubating at 37 °C for 30 min. The 15N213C-3TC and d4ABC internal standard was added at this point. Samples were then loaded onto Waters
OASIS HLB cartridges (60 mg, 30 µm; Waters) pre-conditioned with 3 ml MeOH and 3 ml
H2O and washed with 3.5 ml H2O to remove salts. The nucleosides of interest were then
eluted with 1.5 ml of MeOH and evaporated under vacuum. Once dry, the residue was
reconstituted with a 100 µl of 25% MeOH and stored in the -20 °C freezer until the time of
LC–MS/MS analyses. The LC-MS/MS system comprised of a Waters ACQUITY ultraperformance liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to a
triple quadrupole mass spectrometer with electrospray ionization (ESI) source (Waters
Xevo TQ-XS). For the indirect quantification of TPs, chromatographic separation was
performed with an ACQUITY UPLC using CSH analytical column (2.1×100 mm, 1.7µm;
Waters) equipped with a guard column (Waters, Milford, MA). Mobile phase A consisted
of ammonium bicarbonate (pH 7, 7.5 mM) and mobile phase B was methanol. The flow
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rate was 0.25 ml/min. The initial mobile phase composition was 12 % B for the first 2.5
min, gradually increased to 30 % B over 4 min, gradually increased again to 95 % B over
3.5 min, and then held constant for one min. Mobile phase B was then reset to 12 % over
0.25 min and the column was equilibrated for 2.75 min before the next injection. The total
run time was 13 min. The mass spectrometer was operated in the positive ion mode using
multiple reaction monitoring (MRM). The following transitions were monitored: m/z
230→112 for 3TC, m/z 248→152 for CBV, m/z 287→191 for ABC, m/z 233→115 for the
internal standard (IS)
15

15

N213C-3TC, and m/z 291→195 for IS d4-ABC. 3TC, CBV, ABC,

N213C-3TC, and d4-ABC were detected at a cone voltage of 22, 2, 4, 12, and 2 V,

respectively, and a collision energy of 12, 12, 20, 10, and 20 V, respectively.
3.5.7 Cell viability of ABC and its ProTides.
A CCK-8 Kit was purchased from Dojindo and used to test cell viability after treatment
with ABC and its ProTides. Briefly, MDM plated in a 96-well plate were treated with 100 μl
of 0-400 µM ABC and its ProTides for 24 h. Drug containing medium was removed and
replaced with fresh medium. Ten μl of CCK-8 solution was added to each well followed by
incubation of the plate for 2 h at 37˚C. The absorbance (at 450 nm) of each well was
measured using a microplate reader. The cell viability was calculated according to
manufacturer’s instructions.
3.5.8 Stability Assay in Serum.
The experiment was carried out by adding each ProTide into 100 μl human serum to
reach a final concentration of 15ug/ml in glass vial, and duplicate samples were used for
each ProTide. After incubating the samples at 37 °C with shaking for 24 h, 900 μl of MeOH
was added to stop the reaction. Samples were vortexed for 3min, then centrifuged down
at 16,000 g for 10 min. The supernatants were transfer to new 2 ml tubes and evaporated
to dryness under vacuum. The samples were reconstituted using 50 μl of MeOH, vortexed
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for 3 min and centrifuged down at 16,000 g for 10 min. The supernatants were analyzed
by HPLC for drug concentrations. For control sample (0 min), MeOH were added first to
stop the enzyme before adding the ProTides.
3.5.9 Preparation and characterization of ABC ProTide nanoformulations.
Lipid-PLGA hybrid nanoparticles loaded with AlaMe (NAlaMe) were prepared using a
modified single emulsion solvent evaporation technique as described previously 23. Briefly,
a mixture of lipids consisting of DSPC, DSPE-PEG2k and DSPG in 10:5:1 weight ratio was
coated over drug loaded PLGA nanoparticles to enable sustained release of the loaded
cargo. A 2:1:1 weight ratio of PLGA core to drug to lipid shell was used. NPheMe and
NPheC22 were prepared by high-pressure homogenization (Avestin EmulsiFlex-C3;
Avestin Inc., Ottawa, ON, Canada) as previously reported6. Briefly, PheMe or PheC22 (1%
w/v) and poloxamer 407 (P407, 0.2% w/v) were premixed at room temperature overnight
followed by homogenization at 20,000 psi until the desired particle size and polydispersity
index (PdI) were achieved. Effective diameter (Deff), PdI, and ζ-potential were measured
by dynamic light scattering (DLS) (Malvern Zetasizer Nano Series Nano-ZS, Malvern
Instruments, Westborough, MA, USA).
3.5.10 Cell

uptake

and

retention

of

ABC

phosphoramidate

prodrug

nanoformulations.
Uptake and retention of nanoformulations were determined in MDM as previously
reported3-6,22. Briefly, MDM were treated with different nanoformulations at a concentration
of 100 µM for 1, 2, 4 and 8 h. At select time points, adherent MDM were collected in 1 mL
PBS after washing with 1 mL PBS twice. MDM were pelleted by centrifugation at 3,000
rpm for 8 min. The cell pellet was reconstituted in 200 µl methanol and probe sonication
(10 sec) was used to break the cells and extract drugs. After probe sonication, cell debris
was pelleted by centrifugation at 14,000 rpm for 10 min and 4˚C. The supernatant was
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analyzed for prodrug level using HPLC-UV/Vis. For retention, MDM were treated with 100
µM different nanoformulations for 8 h. The nanoformulation-containing media were
replaced with fresh media after washing MDM with PBS twice. At days 1, 5, 10, 15, 20, 25
and 30, MDM were collected in 1mL PBS after washing with 1 mL PBS twice. The samples
were processed as described above for analysis using HPLC.
Intracellular CBV-TP levels were also measured for as an indicator of cell uptake and
retention. Briefly, cells were scraped into PBS, pelleted by centrifugation at 3,000 rpm for
8 min, and reconstituted in 200 µl 70% methanol. CBV-TP was extracted, and the samples
were analyzed by LC-MS/MS as previously reported21.
3.5.11 Antiretroviral efficacy of nanoformulations.
Antiviral efficacies of ABC and the ProTide nanoformulations in MDM were assessed
as previously described5. MDM were treated with 100 µM different nanoformulations for 8
h. Then nanoformulation-containing medium was replaced with fresh medium after
washing MDM with PBS twice. Half media changes were conducted every other day. At
predetermined time points, days 1, 5 ,10, 15, 20, 25 and 30, MDM were infected with HIV1ADA for 4 h at a MOI of 0.1 and cultured with every-other-day half media changes for an
additional 10 days. At day 10, supernatant was collected for RT assay and MDM were
fixed with paraformaldehyde and immunostained for expression of HIVp24. Untreated,
uninfected MDM served as negative controls (control), while MDM exposed to HIV-1ADA
but not treated with nanoformulations, served as positive controls (HIV-1).
For NPheC22, a concentration response study was also conducted. MDM were
treated with 1, 10, 25, 50 or 100 µM NPheC22 for 8 h. The treated MDM were then washed
twice with PBS. MDM were cultured for an additional 30 days in fresh media with half
media changes every other day. At day 30, MDM were challenged with HIV-1ADA at a MOI
of 0.1 for 4 h. Excess virus was washed out with PBS and MDM were cultured for another
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10 days. At day 10 post-exposure, media were collected for RT assay and MDM were
fixed and immunostained for expression of HIVp24 antigen.
3.5.12 In vivo study with rats.
Animal PK studies were conducted in accordance with the University of Nebraska
Medical Center Institutional Animal Care and Use Committee. Male Sprague Dawley rat
(250g; Jackson Labs, Bar Harbor, ME) were injected with NPheC22 (45 mg/kg ABC-eq.)
intramuscularly (IM; caudal thigh muscle). Whole blood samples were collected at 2, 24
and 168 hours after injection. PBMC were separated from whole blood samples using
HISTOPAQUE 1083 (Sigma# 1083-1) following manufacturer’s instruction. CBV-TP were
extracted and quantified as mentioned above21.
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Figure 3.1 Synthesis Scheme of ABC ProTides.
Reagent and condition: Step 1(a) 1-docosanol, HATU, imidazole, Et3N, DMF/CHCl3,
45 ℃, 48 h; Step 1(b) Pd/C, Et3SiH, MeOH/CHCl3 (1:1 v/v), rt, 16 h. Step 2(a) Phenyl
dichlorophosphate, Et3N, CH2Cl2, -78 ℃-rt, 16 h. Step 3(a) ABC, tert-BuMgCl, THF, -78 ℃rt, 48-90 h.
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Figure 3.2 1H-NMR spectra for ABC, AlaMe, PheMe and PheC22.
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Figure 3.3 13C-NMR spectra for ABC, AlaMe, PheMe and PheC22.
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Figure 3.4 31P-NMR spectra for AlaMe, PheMe and PheC22.
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Figure 3.5 FTIR spectra of ABC, AlaMe, PheMe and PheC22
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Figure 3.6 The structure and biological characterization of ABC and its ProTides.
A. AlaMe, PheMe and PheC22 were synthesized based on ProTide technology. B.
EC50 of ABC, AlaMe, PheMe and PheC22 against HIV-1ADA were determined in MDM. C.
Intracellular CBV-TP levels were measured after MDM were treated with 10 μM free ABC,
AlaMe, PheMe and PheC22 for various times. D. Cytotoxicity of ABC, AlaMe, PheMe and
PheC22 in MDM. Results are shown as percentage of cell viability as compared to
untreated MDM. Data are presented as mean ± SD for n=3 samples per group.
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Figure 3.7 Preparation and characterization of nanoformulations.
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A. NAlaMe was prepared by a modified single emulsion solvent evaporation technique.
B. NPheMe and NPheC22 were produced by high pressure homogeinization. C. TEM
images of NAlaMe, NPheMe and NPheC22.
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Table 3.1 Characterization of Nanoformulationsa
Name

Deff (nm)

PdI

ζ- potential
(mV)

Drug loading
(%)

NAlaMe

237 ± 2

0.15 ± 0.03

- 43.4 ± 0.7

3.4 ± 0.2

NPheMe

339 ± 17

0.35 ± 0.01

- 14.3 ± 0.3

43.4 ± 0.5

NPheC22

329 ± 3

0.28 ± 0.01

- 45.0 ± 0.4

47.4 ± 2.0

Effective diameter (Deff), polydispersity index (PdI) and ζ- potential of nanoformulation
samples diluted in water were determined by dynamic light scattering (DLS). Drug
loadings of lyophilized nanoformulations were determined by HPLC. Drug loading (%) =
[entrapped drug/nanoparticles weight] x 100. Data are expressed as mean ± SD.
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Figure 3.8 Uptake and retention of nanoformulations in MDM.
A and B. For cell uptake, MDM were treated with 100 μM ABC or prodrug
nanoformulations for 8 hr. C and D. Drug retention in MDM was determined after an 8 h
drug loading followed by half media exchanges every other day for up to 30 days.
Intracellular drug concentrations and CBV-TP levels were determined. Data are expressed
as mean ± SD for n = 3 samples per group. E. TEM was performed to visualize
morphologies of formulation-loaded MDM after 8 h incubation with nanoformulations.
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Figure 3.9 ABC ProTide nanoformulations protect MDM from HIV-1 infection
over time.
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MDM were treated with free ABC or nanoformulations of ABC ProTides containing 100
μM ABC equivalent for 8 h. At predetermined time points, MDM were challenged with HIV1ADA. Samples were collected for antiretroviral activity assessment ten days after viral
challenge by (A) measuring HIV RT activities and (C) staining HIV-1p24 antigen. (B) and
(D) MDM were treated with 1, 10, 25, 50 and 100 μM NPheC22 for 8 h. At day 30 post
treatment, MDM were challenged with HIV-1ADA. Ten days after infection, culture media
were collected for RT assay and cells were fixed and stained for HIV-1p24 antigen. Data
are expressed as mean ± SD for n = 3 samples per group.
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Table 3.2 CBV-TP level in PBMC for pilot in vivo study
CBV-TP level (fmol/million cells)
Time (Hours)
Rat 1

Rat 2

2

1.07

7.84

24

4.23

5.36

168

4.51

9.37

Rats were injected Intramuscularly with 45mg/kg ABC equivalents using NPheC22. PBMC
were extracted from whole blood samples collected 2, 24 and 168 hours after injection.
CBV-TP level were analyzed as reported21.
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Chapter 4
Optimization of Nanoformulated ABC ProTides LA
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4.1 Abstract
Nucleoside analogs transcriptase inhibitor (NRTIs) served as the “backbone” of
antiretroviral drug regimen. But, the properties of NRTIs limit their possibilities for the
redevelopment as long-acting injectable products using conventional pharmaceutical
manufacturing approaches. In the first phase of application of LASER ART, we reduced
the solubility of ABC by conjugating it with myristoyl chloride (MABC) and successfully
nanoformulated MABC by high pressure homogenization. Detectable level of ABC was
observed during the whole 14-day time period in vivo study, Then, we have tried to develop
second generation long-acting (LA) ABC nanoformulation by adding ProTides technology
to our LASER ART platform. The developed ABC ProTide LA showed significant
improvements in terms of both potency and extended release. In this chapter, we
synthesized a variety of ABC ProTides LA with different combination of amino acid side
chains and fatty alcohols and their in vitro/ in vivo behaviors were thoroughly examined.
4.2 Introduction
Exciting breakthroughs have been continuously reported in HIV/AIDS research.
However, before the appearance of a safe, affordable and repeatable cure, the powerful
combined antiretroviral drug “cocktail” remains as the gold standard for HIV/AIDS
treatment. And patients can expect a normal life as compared to uninfected people.
Moreover, a lot of “cure” strategies proposed still rely on antiretroviral drugs to suppress
the viral replication and reduce the viral reservoirs. In recent years, long-acting (LA)
formulations for the delivery of antiretroviral drugs and treatment of HIV/AIDS have
received much attention since LA agents have the potential advantages of requiring lessthan-daily dosing intervals, improving pharmacokinetic profile of antiretroviral drugs and
reducing the risk of viral mutation and drug resistance caused by missed doses. Two LA
injectable agents, cabotegravir (GSK1265744 LA, CAB LA, integrase inhibitor) and
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rilpivirine (TMC278 LA, RPV LA, Non-nucleoside reverse transcriptase inhibitor), are in
advanced stages of clinical trials now.
On the other hand, nucleoside analogs transcriptase inhibitor (NRTIs) served as the
“backbone” of antiretroviral drug regimen. Generally, two NRTIs are used along with a
drug from other classes. But, the dosing frequency of LA reagent is determined by the
drug’s aqueous solubility/hydrophobicity, antiretroviral potency/daily dose and system
clearance/half-life1 which means all the approved NRTIs are not suited for redevelopment
as long-acting injectable products using conventional pharmaceutical manufacturing
approaches. For example, the solubility, EC50/daily dose and half-life of abacavir (ABC)
are 2 mg/ml, 0.07 to 5.8 μM/600 mg (8.6 mg/kg), 1.54 h (20 h for CBV-TP), while they
were 0.1 mg/ml, 0.22 to 1.3 nM/0.30 mg (0.4 mg/kg), 40 h for CAB. However, in order to
achieve equivalent therapeutic drug exposure for LA formulation when compared with
daily, oral version of NRTIs, the solubility and antiviral potency of NRTIs definitely need to
be adjusted in scale of one or two orders of magnitude and that is the strength of our
LASER ART platform. We have reduced the solubility of ABC by conjugating it with
myristoyl chloride (MABC) and successfully nanoformulated MABC by high pressure
homogenization2. Detectable level of ABC was observed during the whole 14-day time
period in vivo study, while the CBV-TP level was not ideal3. Clearly, the antiretroviral
activity of ABC also needs to be adjusted. In the last two chapters, we have proved that
ProTide technology can be used for this purpose. The developed ABC ProTide LA showed
significant improvements in terms of both potency and extended release6. In this paper,
we dived further in to this strategy, a variety of ABC ProTides LA with different combination
of amino acid side chains and fatty alcohols have been synthesized and their in vitro/ in
vivo behaviors were thoroughly examined.
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4.3 Results
4.3.1 Synthesis of ABC ProTides LA
Six ABC ProTides were synthesized with high yields (Figure 4.1). The chemical
structure of ABC ProTides was characterized by 1H NMR, 13C-NMR, 31P NMR and FT-IR
spectra and compared to ABC as shown in Figurs 4.2-4.5. A broad singlet at 1.26 ppm
correspond to the repeating methylene protons of the fatty acid alkyl chain ABC ProTides.
Multiplet at 7.96 - 9.16 ppm correspond to the benzene ring protons. Splitting of peaks in
the 31P-NMR spectra of ProTides was associated with co-existence of two stereoisomers
at the phosphorus atom16. In addition, absorption bands at 2855 and 2923 cm−1 in the FTIR spectrum associate with the C-H stretches of the fatty acid ester chain. A band at
1760 cm−1 is attributed to the carbonyl C=O stretch of the ester bond present in the fatty
esters.
4.3.2 Antiretroviral activity and Cytotoxicity of ABC ProTides LA
At least 5-fold improvements of EC50 were observed with ABC ProTides against HIV1ADA in MDM (Table 4.1). The EC50 of ABC was 21.4 nM while the EC50 for AlaC14, AlaC18,
AlaC22, PheC14, PheC18 and PheC22 were 1.1, 2.2, 3.7, 0.18, 1.3 and 3.4 nM,
respectively. These improvements have not been seen with myristoylated abacavir
(MABC)2 and supported the rationale design of second-generation ABC LA. Similarly,
improvements of antiretroviral efficacy were also observed for ABC ProTides against HIV1NLF-3 in CEM CD4+ T cells but to a less extent. The EC50 of ABC was 2.66 μM. However,
for ABC ProTides, they were 0.24, 0.30, 2.20 and 1.21 μM for AlaC14, AlaC18, AlaC22
and PheC14, respectively. PheC18 and PheC22 were less potent as compared to ABC,
and the EC50 of PheC18 and PheC22 were 25.64 and 43.03 μM, respectively. In general,
the EC50 of ABC ProTides increased with longer fatty acid esters. L-phenylalanine based
ABC ProTides were more potent than L-alanine based ABC ProTides in MDM but not in
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CEM CD4+ T cells. This was probably because MDM unlike T cells contained numerous
enzymes that might even include chymotrypsin-like esterase and Cathepsin G, which are
responsible for the metabolized of ABC ProTides especially L-phenylalanine based ones7.
The Cytotoxicity of ABC ProTides were also measured. Since the highest drug
concertation tested is 400 μM, the CC50 level could not be accurately calculated. However,
while ProTides did show increases in cytotoxicity, the selectively index (SI) was still more
favorable compared to ABC especially for alanine-based ProTides, similar to previous
report8.
4.3.3 Intracellular CBV-TP level
It was reported9 that the improved antiretroviral activity of ABC ProTide was due to
markedly increase of its metabolite (CBV-TP) inside the cells. As Figure 4.6A shows, in
MDM, during the 48-h incubation time period, the CBV-TP level of ABC ProTide treatment
groups were at least 2-fold higher than ABC. Specifically, 6 h after incubation, the CBVTP level for ABC was 61.8 fmol/10^6 cells, and 2820.6, 2339.7, 1523.6, 378.7, 356.4 and
157.8 fmol/10^6 cells for AlaC14, AlaC18, AlaC22, PheC14, PheC18 and PheC22,
respectively. 48 hr after incubation, the CBV-TP level for ABC was 40.84 fmol/10^6 cells,
and 264.9, 207.5, 890,9, 282.5, 392.8, 692.0 fmol/10^6 cells for AlaC14, AlaC18, AlaC22,
PheC14, PheC18 and PheC22, respectively. For Ala-based ProTides, CBV-TP levels
reached higher Cmax soon after incubation then the levels decreased faster. For Phebased ProTides, the CBV-TP levels were more stable and showed very slow decrease
rate. In general, Ala-based ProTides had higher Cmax but Phe-based ProTides had higher
C48hr.
CBV-TP levels were also recorded in CEM CD4+ T cells (Figure 4.6B) after incubated
with free ABC ProTides. In general, the CBV-TP levels were higher or similar in T cells as
compared to in MDM, especially for ABC, although ABC and ABC ProTides was
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significantly more potent in MDM than in T cells. This observation had been reported
before and was explained by the fact that dNTP pool levels is markedly lower in MDM than
in T cells, thus CBV-TP can better compete with dNTP as the substrate for HIV reverse
transcriptase9. Another difference was that CBV-TP levels kept rising during the 48 hr
incubation time period for ABC and all ABC ProTides treatment in T cells. 7,5- and 4.9fold higher CBV-TP levels were recorded for AlaC14 (2082.7 fmol/10^6 cells) and AlaC18
(1346 fmol/10^6 cells) as compared to ABC (276.73 fmol/10^6 cells) at 48 hr. Other ABC
ProTides showed less CBV-TP level as compare to ABC, but the trends correlated with
EC50 results. Again, there were significantly negative correlation between chain length of
fatty esters and drug potency against HIV-1 (CBV-TP level).
4.3.4 Metabolic stability assay in serums
The stability of ABC ProTides in circulation is very impotent, premature degradation of
ProTides will diminish their cell membrane penetration ability and reduce their potency.
As Figure 4.7 shows, all ABC ProTides except AlaC14 were stable after 24 h incubation
with human serum, while AlaC14 and PheC14 suffered seriously degradation when
incubating with the rat serum. The level of AlaC18 was also slightly decreased in rat serum.
This difference is possibly attributed to the species difference of esterase expression and
hydrolase activity. It was reported circulated carboxylesterase (CES) was only abundant
in rabbits, mice and rats, but not in primates10. And CES1 is proposed to be responsible
for the intracellular activation of TAF in human for the treatment of HBV. These results
suggested that interpretation of pharmacokinetic data conducted in rodent model need to
consider the possibility of premature degradation of ProTides in the circulation.
4.3.5 Preparation and characterization of ABC ProTide LA nanosuspensions
ABC ProTides nanosuspensions were prepared successfully by high-pressure
homogenization with high drug loading (Figure 4.8, Table 4.2). Intensity-mean Z91

averaged particle diameter (Deff), ζ-potential, and polydispersity index (PdI) of
nanosuspensions determined by DLS were also summarized in Table 4.2. All ABC Protide
nanosuspensions had sizes around 250 - 300 nm with PdI<0.3 and negative surface
charges. As observed by TEM, all nanosuspensions had spherical shape. When store at
4 ℃, the size of NAlaC14 increased 24% after seven days, while NAlaC18 and NAlaC22
were stable for at least one month. Similar trends were observed for phenylalanine-based
ABC ProTides (data not shown). It was suggested LogP of a drug positive correlated with
the particle stability11. The cLogP calculated by ChemDraw was 5.2, 7.3 and 9.4 for
AlaC14, AlaC18 and AlaC22, respectively.
4.3.6 Uptake, retention and release studies in MDM.
Cell viability assay revealed that all ABC ProTides LA nanosuspensions with drug
concentration up to 400 µM had no or little cytotoxic effect on MDM after 8 h incubation.50
µM ABC or ABC ProTide nanosuspensions was selected for MDM based in vitro study.
As Figure 4.9A-B shows, in MDM uptake study, NPheC18 and NPheC22 had the highest
prodrug levels, followed by NAlaC22, NAlaC18, NPheC14 and NAlaC14. However, in
terms of CBV-TP levels during the uptake study, NAlaC14 treatment group had the highest
CBV-TP level (19673.2 fmol/10^6 cells), followed by NAlaC18 (7966.0 fmol/10^6 cells),
NAlaC22 (3798.1 fmol/10^6 cells), NPheC14 (2449.1 fmol/10^6 cells), NPheC18 (994.4
fmol/10^6 cells) and NPheC22(1492.0 fmol/10^6 cells) at 8 h while the CBV-TP level for
ABC was 698.0 fmol/10^6 cells. Obviously, the hydrophobicity and lipophilicity of each
ProTide affected or determined the results of this uptake study. For AlaC18, PheC22, and
AlaC22 with higher hydrophobicity and lipophilicity, their nanoparticles were comparable
stable inside the cell and showed higher prodrug levels. While NAlaC14, once inside the
cells, was immediately digested, and AlaC14 was released and metabolized to its
metabolites.
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The hydrophobicity and lipophilicity of each ABC ProTide also had influence on their
retention results (Figure 4.9C-D). For Ala-based ProTides, the prodrug levels of NAlaC14
or NAlaC18 treatment group was under detection limit at day 1 or day 14, respectively,
while the prodrug level for NAlaC22 (1.5 nmol/10^6 cells) was still above detection level
until day 28. For Phe-based ProTides, similar results were observed, but since Phe-based
ProTides were more hydrophobic then their Ala-based counterparts, prodrug level for
NPheC14 was detectable up to day 14, while NPheC18 and NPheC22 treatment group
showed high amounts of prodrugs were still retained inside the MDM at day 28. The
prodrug level of NPheC22 treatment group was decreased in a strikingly slow rate. CBVTP levels in MDM for retention study were correlated with the prodrug levels. They are
696.0, 1145.7, 1382.7, 317.0, 1332.1 and 1256.7 fmol/10^6 at day 1, respectively, then
the levels slowly decreased to 29.0, 110.8, 435.0, 132.02, 447.0 and 294.3 fmol/10^6 cells
for NAlaC14, NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22, at day 28,
respectively. CBV-TP level for ABC treatment group was 10.7 fmol/10^6 cells then fell
below detection level at day 3.
We have collected media from long-acting dolutegravir (NMDTG) treated MDM, and
treated CD4+ T cells with such media. Results showed that this drug-containing media
released by MDM was able to protect CD4+ T cells against HIV infection up to day 2412.
Since it is as important for MDM to release enough drugs to other cells as retain enough
drugs for other cells include T cells and MDM itself against HIV infection, whole media
changes were always conducted one day before the cell collection time of retention study,
then the media were collected and analyzed to study the release profile of each treatment
group (Figure 4.9E). No prodrug had been detected for NAlaC14 treatment group at day
1, which, again, suggested that all AlaC14 delivered into the cells had been metabolized.
For NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22, the prodrug levels were 11.7,
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8.7, 17.2, 7.1 and 1.6 nmol/10^6 cells, respectively. Higher release rate was observed for
Ala-based ProTides as compared to its Phe-based counter parts in an order C14> C18>
C22. Moreover, particles had size range between 50-150 nm has been detected in the
media and was stained positive for one of the exsosome marker ALIX (data no shown).
ExoquickTM was used to extract such particles, both CBV-TP and prodrugs can be
detected inside those particles (no prodrug can be detected for NAlaC14 treatment group).
When incubated these particles with CD4+ T cells, uptake of these particles can also be
measured. These particles released by MDM might serve as a carrier to disseminate CBVTP and prodrugs, it might also help targeting T cells or other reservoirs13, which are worth
further investigation.
4.3.7 In vitro antiretroviral study in MDM.
To determine whether sustained intracellular prodrug and CBV-TP level from ProTide
formulations would translate into improved antiretroviral activity, MDM were challenged
with HIV-1ADA for up to 28 days after a single 8 h treatment with 50 µM ABC equivalent
dose of different nanosuspensions. HIV-1 reverse transcriptase (RT) activity and p24
antigen expression were assessed in infectious supernatants and adherent MDM on day
10 post-infection. As shown in Figure 4.10, complete total viral inhibition was observed
for up to 28 days for NAlaC18, NAlaC22, NPheC14, NPheC18 and NPheC22 measured
by RT assay. At day 28, 8.5 % RT activity was recorded for NAlaC14. HIV-1p24 antigen
staining confirmed these results. In contrast, minimal protection against viral infection was
observed with native ABC at all time points. These results paralleled prolonged high
intracellular CBV-TP levels for all the ABC ProTides nanosuspension treatment group.
4.3.8 In vivo pharmacokinetic study.
To investigate the in vivo behavior of nanoformulated ABC ProTides, male Sprague
Dawley rat were injected intramuscularly with ABC, NAlaC14, NAlaC18, NAlaC22 and
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NPheC18 (70 mg/kg ABC-eq. and 10mg/kg human dose-eq.). For ABC, the CBV-TP level
was decreased from 488.22 to 25.42 fmol/10^6 cells within one day and was below
detection level at day 7 (Figure 4.11B). For NAlaC14, unlike ABC, the CBV-TP level
(44.17 fmol/10^6 cells) peaked at day 1 and was 3.3 fmol/10^6 cells at day 7 with a range
of 1.73 to 6.19 fmol/10^6 cells. NAlaC18 also had Cmax (18.4 fmol/10^6 cells) at day 1, and
the CBV-TP level only decreased by 2-fold at day 7 (9.74 fmol/10^6 cells), the level was
still about detection level at day 14 (0.42 fmol/10^6 cells). For NAlaC22 and NPheC18, we
observed constant level of CBV-TP level (around 1-2 fmol/10^6 cells) up to day 7 or day
14. Quantifiable amounts of CBV-TP level can be detected for NPheC18 until day 28 (0.5
fmol/10^6 cells). It is worth to mention, we detected 2% AlaC18 in NAlaC14 later which
might affect the results to some degree.
4.4 Discussion
In the development of LA nanoformulation, the perfect candidates should be able to
maintain sustained but effective level of drugs over a period of time. Specifically, MDM
was reported, first, one of the target cells and reservoir for HIV infection and replication.
And it also served as a carrier for the delivery of drugs to other cells and tissues17.
Moreover, MDM actively affect the pharmacokinetics profile of LA nanoformulation, it can
serve as secondary depots and modify the dissolution and release of drugs from
formulations14-16.
By employing the ProTide technology, we were able to improve the potency of drugs
up to 100-fold or 10-fold in MDM or CEM CD4+T cells against HIV infection. The active
metabolite CBV-TP was also increased by up to 45-fold of 8-fold in MDM or CEM CD4+T
cells. By applying our lab’s expertise on top of that, potent and long-acting ABC ProTides
nanoformulations were developed. In our study, we observed improved uptake, retention
and release profiles of ABC ProTides nanoformulation in MDM as compare to ABC.
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Significant sustained and high amounts of CBV-TP were observed in all ABC ProTides
nanoformulations treated MDM and protected MDM against HIV infection up to day 30. It
is possible CBV-TP and prodrugs can both released by treated MDM. ProTides modified
with myristyl alcohol (C14) has the highest release rate, followed by stearyl modified
alcohol (C18) from nanoformulations treated MDM. Docosyl modified ProTides (C22),
especially PheC22, was released from MDM at a small but very constant amounts.
This in vitro observation almost paralleled exactly to what we observed in in vivo study.
In general, as compare to ABC, sustained release was observed with all tested ABC
ProTides nanoformulations. Among them, NAlac14 had highest Cmax, but CBV-TP level
decreased 13-fold during the first week, while only 2-fold difference of CBV-TP level was
observed for NAlaC18. Constant CBV-TP levels were observed for NAlaC22 and
NPheC18. In this study, we were able to achieve clinically relevant CBV-TP level, reported
by GSK in study CNA 10905, with NAlaC18 for seven days with single injection at 10mg/kg
human dose equivalent. While it is worth to mention that species differences might affect
the pharmacokinetics outcomes. We did observe our ABC ProTides are less stable in
human serum which might diminished their penetration into cells. Moreover, metabolism
and clearance rate are slower in human as compared to rat which might leads to higher
CBV-TP level that will last longer. Such phenomenon has been reported for RPV LA, which
has been tested in both rat and human18. Further investigation is needed for our longacting ABC ProTide nanoformulations.
In conclusion, we have successfully proved in this chapter that our strategy, combining
ProTides technologies with LASER ART developed in our lab, can improved both antiviral
potency and release profiles of NRTIs using ABC as example. This may pave the way
towards the development of an actual LA injectables of NRTIs for clinics, which can not
only be used to HIV/AIDS but other disease.
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4.5 Methods.
4.5.1 Reagents.
All chemical synthesis reactions were performed under a dry argon atmosphere unless
otherwise noted. Reagents were obtained from commercial sources and used directly;
exceptions are noted. Abacavir was purchased from BOC Sciences Inc. (Shirley, NY).
phenyl dichlorophosphate, N-(carbobenzyloxy)-L-phenylalanine, N-(carbobenzyloxy)-Lalanine, tetradecanol, octadecanol, docosanol, dichloromethane (CH2Cl2), chloroform
(CHCl3),

N,N-dimethylformamide

(DMF),

triethylamine

(Et3N),

diethyl

ether,

tetrahydrofuran (THF), tert-Butylmagnesium chloride solution (tert-BuMgCl, 1.0M in THF),
triethylsilane (Et SiH), methanol and poly (D, L-lactide-co-glycolide; lactide:glycolide
3

(75:25), mol wt 66,000-107,000) (PLGA) were purchased from Sigma-Aldrich (St. Louis,
MO). Distearoyl-phosphatidylethanolamine-methyl-polyethylene glycol conjugate-2000
(DSPE-mPEG2k)

was

purchased

from

Corden

Pharma

[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]

(Cambridge,
pyridinium

MA).

1-

3-oxid

hexafluorophosphate (HATU) was obtained from Bachem Inc. (Torrance, CA) while
palladium, 10% on activated carbon, was purchased from STREM Inc. (Newburyport, MA).
Flash chromatography was performed using flash silica gel (32-63 μ) from SiliCycle Inc.
(Quebec, Canada). Chemical reactions were analyzed by thin layer chromatography
(T.L.C) on precoated silica plates (200 μm, F-254) from Sorbtech technologies Inc.
(Norcross, GA). The compounds were visualized by UV fluorescence or by staining with
ninhydrin or KMnO4 reagents. CD68 Polyclonal Antibody (Catalog # PA5-78996) was
purchased from Thermo Fisher Scientific.
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4.5.2 Synthesis of ABC ProTides LA
ABC ProTides were synthesized as previously reported6,8. Briefly (Scheme 1), alanine
or phenylalanine esters were prepared with HATU/TEA/imidazole through esterification of
Cbz-protected amino acid and long-chain fatty alcohols followed by removal of Cbz. Then,
the aryl amino acid ester phosphorochloridates were synthesized from amino acid esters
with commercially available phenyl phosphorodichloridate in the presence of TEA. Each
of the amino acid ester phosphorochloridates was then reacted with ABC in the presence
of tert-BuMgCl and purified by flash column chromatography with DCM/MeOH. Successful
synthesis of ABC ProTides was confirmed by 1H, 13C and 31P NMR spectra.
AlaC14: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 5.9 Hz, 1H), 7.31 (dd, J = 14.3, 7.6
Hz, 2H), 7.12-7.20 (m, 4H), 6.13-6.17 (m, 1H), 6.09-6.12 (m, 1H), 5.91-5.97 (m, 1H), 5.465.54 (m, 1H), 4.15-4.24 (m, 1H), 4.13 (t, J = 5.6 Hz 1H), 3.97-4.08 (m, 2H), 3.89 (td, J =
15.8, 7.5 Hz, 1H), 3.12-3.23 (m, 1H), 2.91 (br, 1H), 2.73-2.84 (m, 1H), 1.63-1.76 (m, 1H),
1.57 (p, J = 6.4 Hz, 2H), 1.20-1.36 (m, 28H), 0.89 (t, J = 6.9 Hz 3H), 0.83 (dd, J = 12.0,
6.8 Hz, 2H), 0.56-0.63 (m, 2H).

13

C NMR (125 MHz, CD3OD): δ 175.1, 161.7, 157.5,

152.2, 152.1, 137.9, 137.1, 131.8, 130.7, 126.0, 121.4, 121.3, 114.8, 70.1, 70.0, 66.4,
60.4, 51.5, 47.1, 35.5, 33.1, 30.8, 30.7, 30.6, 30.4, 30.3, 29.7, 26.9, 24.3, 23.7, 20.5,
20.4, 14.4, 7.6;

31

P NMR (CD3OD); 3.87, 3.56. MS-ES+ (m/z): calcd. for C37H56N7O5P,

709.41 (100%), 710.41 (40.0%), 711.41 (7.8%); found, 710.4[M+H+].
AlaC18: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 6.0 Hz, 1H), 7.30 (dd, J = 14.2, 7.5
Hz, 2H), 7.11-7.20 (m, 3H), 6.13-6.18 (m, 1H), 6.09-6.12 (m, 1H), 5.92-5.97 (m, 1H), 5.465.55 (m, 1H), 4.14-4.24 (m, 1H), 4.13 (t, J = 5.6 Hz, 1H), 3.97-4.08 (m, 2H), 3.90 (td, J =
15.6, 7.3 Hz, 1H), 3.12-3.23 (m, 1H), 2.91 (br, 1H), 2.72-2.83 (m, 1H), 1.63-1.75 (m, 1H),
1.57 (p, J = 6.3 Hz, 2H), 1.20-1.35 (m, 33H), 0.89 (t, J = 6.9 Hz 3H), 0.83 (dd, J = 12.0,
6.8 Hz, 2H), 0.56-0.62 (m, 2H).

13

C NMR (125 MHz, CD3OD): δ 175.1, 161.9, 157.5,
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152.3, 152.1, 138.6, 138.0, 137.9, 137.1, 136.9, 131.8, 130.7, 126.0, 121.4, 121.3, 70.1,
70.0, 60.4, 60.3, 47.1, 37.0, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.3, 29.7, 26.9, 24.3,
23.7, 20.6, 20.4, 14.5, 7.6;

31

P NMR (CD3OD); 3.86, 3.54. MS-ES+ (m/z): calcd. for

C41H64N7O5P, 765.47 (100%), 766.47 (44.3%), 767.48 (9.6%); found, 766.4[M+H+].
AlaC22: 1H NMR (500 MHz, CD3OD): 7.64 (d, J = 5.7 Hz, 1H), 7.31 (dd, J = 13.9, 7.7
Hz, 2H), 7.22-7.29 (m, 1H), 7.12-7.19 (m, 4H), 6.13-6.17 (m, 1H), 6.09-6.12 (m, 1H), 5.925.97 (m, 1H), 4.15-4.24 (m, 1H), 4.14 (t, J = 5.6 Hz, 1H), 3.98-4.08 (m, 2H), 3.89 (td, J =
15.5, 7.7 Hz, 1H), 3.12-3.24 (m, 1H), 2.91 (br, 1H), 2.72-2.84 (m, 1H), 1.61-1.76 (m, 1H),
1.58 (p, J = 6.3 Hz, 2H), 1.17-1.38 (m, 42H), 0.89 (t, J = 6.9 Hz 3H), 0.84 (dd, J = 12.0,
6.8 Hz, 2H), 0.56-0.62 (m, 2H).

13

C NMR (125 MHz, CD3OD): δ 175.1, 161.9, 157.5,

152.3, 152.2, 151.7, 137.9, 137.0, 131.8, 130.7, 126.0, 121.4, 121.3, 114.9, 70.1, 70.0,
66.4, 60.5, 60.3, 51.7, 51.6, 47.1, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.4, 29.7, 26.9,
24.3, 23.7, 20.6, 20.4, 14.5, 7.6;

31

P NMR (CD3OD); 3.86, 3.55. MS-ES+ (m/z): calcd.

for C45H72N7O5P, 821.53 (100%), 822.54 (48.7%), 823.54 (11.6%); found, 822.5[M+H+].
PheC14: 1H NMR (500 MHz, CD3OD): 7.59 (s, 0.5H), 7.54 (s, 0.5H), 7.09-7.30 (m,
8H), 7.02-7.07 (m, 2H), 6.01-6.05 (m, 1H), 5.86-5.94 (m, 1H), 5.42-5.49 (m, 1H), 4.09 (dd,
J = 15.3, 8.9 Hz, 1H), 3.91-4.02 (m, 2H), 3.70-3.84 (m, 1H), 3.62-3.67 (m, 1H), 2.97-3.09
(m, 1H), 2.78-2.95 (m, 3H), 2.68 (td, J = 14.7, 8.6 Hz 1H), 1.45-1.58 (m, 3H), 1.18-1.35
(m, 23H), 0.89 (t, J = 6.8 Hz, 3H), 0.81-0.86 (m, 2H), 0.56-0.62 (m, 2H).

13

C NMR (125

MHz, CD3OD): δ 174.2, 161.9, 157.5, 152.2, 138.6, 138.4, 138.3, 138.0, 137.0, 131.7,
131.6, 130.7, 130.6, 129.5, 127.9, 125.9, 121.4, 121.2, 114.9, 69.8, 66.4, 60.4, 58.1,
57.9, 46.9, 41.0, 36.9, 35.5, 33.1, 30.8, 30.7, 30.6, 30.5, 30.3, 29.6, 26.9, 24.3, 23.7,
14.5, 7.6; 31P NMR (CD3OD); 3.57, 3.24. MS-ES+ (m/z): calcd. for C43H60N7O5P, 785.44
(100%), 786.44 (46.5%), 787.45 (10.6%); found, 786.4[M+H+].
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PheC18: 1H NMR (500 MHz, CD3OD): 7.59 (s, 0.5H), 7.54 (s, 0.5H), 7.08-7.32 (m,
8H), 7.02-7.08 (m, 2H), 5.85-5.93 (m, 1H), 5.41-5.49 (m, 1H), 4.08 (dd, J = 17.9, 8.9 Hz,
1H), 3.90-4.03 (m, 2H), 3.72-3.85 (m, 1H), 3.60-3.67 (m, 1H), 2.96-3.09 (m, 1H), 2.782.95 (m, 3H), 2.68 (td, J = 15.4, 8.6 Hz 1H), 1.44-1.57 (m, 3H), 1.15-1.35 (m, 33H), 0.89
(t, J = 6.8 Hz, 3H), 0.81-0.86 (m, 2H), 0.56-0.63 (m, 2H). 13C NMR (125 MHz, CD3OD): δ
174.1, 161.7, 157.4, 152.2, 152.1, 151.6, 138.3, 138.2, 138.0, 137.9, 137.0, 131.6,
130.7, 130.6, 130.5, 130.1, 130.0, 129.5, 127.9, 125.9, 121.3, 121.2, 114.8, 69.8, 69.7,
66.4, 60.4, 58.0, 57.7, 46.9, 41.1, 41.0, 35.5, 33.1, 30.8, 30.6, 30.5, 30.4, 30.3, 29.6,
24.4, 23.7, 14.5, 7.6;

31

P NMR (CD3OD); 3.56, 3.24. MS-ES+ (m/z): calcd. for

C47H68N7O5P, 841.50 (100%), 842.51 (50.8%), 843.51 (12.6%); found, 842.5[M+H+].
PheC22: 1H NMR (500 MHz, CD3OD): 7.59 (d, J = 28 Hz 1H), 6.95-7.44 (m, 11 H),
6.04 (br, 1H), 5.88-5.95 (m, 1H), 5.48 (br, 1H), 4.13 (d, J = 15.2, 8.7 Hz 1H), 3.89-4.09 (m,
3H), 3.47-3.59 (m, 2H), 2.64-3.15 (m, 5H), 1.45-1.64 (m, 3H), 1.07-1.39 (br, 42H), 0.91 (t,
J = 6.6 Hz 3H), 0.84-0.87 (m, 2H), 0.61 (br, 2H). 13C NMR (125 MHz, CD3OD): δ 174.2,
157.4, 154.3, 152.1, 144.9, 138.3, 138.2, 138.0, 137.9, 137.1, 131.5, 130.6, 130.5,
130.3, 130.1, 129.6, 128.9, 127.9, 126.7, 125.9, 124.1, 121.9, 121.4, 121.3, 121.1,
114.8, 69.9, 66.7, 66.4, 63.2, 60.4, 58.1, 57.8, 46.8, 41.1, 35.4, 33.1, 31.2, 30.7, 30.5,
29.6, 29.5, 26.9, 23.8, 14.5, 7.6; 31P NMR (202 MHz, CD3OD); 3.25, 3.54. MS-ES+ (m/z):
calcd. for C51H76N7O5P, 897.56 (100%), 898.57 (55.2%), 899.57 (14.9%); found, 898.56
[M+H+].
4.5.3 Cell culture
Human peripheral blood monocytes were obtained and cultured as previously
described19,20. Briefly, monocytes were obtained by leukapheresis followed by purification
via countercurrent centrifugal elutriation. Elutriated monocytes were cultured as adherent
cells at 37 °C in a 5% CO2 incubator in DMEM supplemented with 10% heat-inactivated
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pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1000 U/mL
recombinant macrophage colony stimulating factor. Seven days later, differentiated
macrophages (MDM) were ready for study. Human T lymphoblastoid cell line CEM CD4+
and CEM-ss were obtained through NIH AIDS Reagent Program and maintained at 37°C
in 5% CO2 in RPMI medium (Sigma) supplemented with 10% FBS and 1% Penicillin
Streptomycin.
4.5.4 EC50 and CC50 of ABC ProTides LA.
The antiviral activities (EC50) of native ABC and ABC ProTides against HIV-1ADA were
determined in MDM and CEM CD4+ T cells as previously described2. MDM or CEM CD4+
T cells were incubated with various concentrations of ABC or ABC ProTides for 60 min
followed by infection with HIV-1ADA or HIV-1NLF-3 at a multiplicity of infection (MOI) of 0.01.
The MDM or CEM CD4+ were washed extensively with phosphate buffered saline (PBS)
to remove excess virus particles. The cells were incubated an additional 10 days in the
presence of the same concentration of drug used before infection. Cell culture medium
was changed every other day with replacement of equivalent drug containing media. At
day 10 post infection, supernatants were collected for and analyzed by HIV reverse
transcriptase assay.
The cytotoxicity of ABC and its ProTides were measured by CellTiter-Blue® Cell
Viability Assay. Briefly, MDM or CEM CD4+ T cells were plated in a 96-well plate and
treated with 100 μl of 0 ~ 400 µM of ABC and its ProTides for 24 h. Then drug contained
media were removed and replaced by fresh media, and 20 μl of CellTiter-Blue® reagent
were added to each well followed by incubating the plate for 1-2 h in the incubator. The
absorbance of each well was measured using a microplate reader with excitation 560 nm
and emission 590 nm. The cell viability was calculated according to manufacturer’s
instruction.
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4.5.5 Metabolic stability of ABC ProTides
The experiment was carried out by adding each ProTide into 300 μl human serum or
rat serum to reach a final concentration of 15 ug/ml in glass vial, and duplicate samples
were used for each ProTide. After incubating the samples at 37 °C with shaking for 6, 24
h, 1.5 ml of MeOH was added to stop the reaction. Samples were vortexed for 3 min, then
centrifuged down at 17,000 g for 10 min. The supernatants were transfer to new 2 ml tubes
and evaporated to dryness under vacuum. The samples were reconstituted using 50 μl of
MeOH, vortexed for 3 min and centrifuged down at 17,000 g for 10 min. The supernatants
were analyzed by HPLC for drug concentrations. For control sample (0 min), MeOH were
added first to stop the enzyme before adding the ProTides.
4.5.6 Measurements of Intracellular CBV-TP level
Intracellular levels of CBV-TP were measured similar to previously described9. MDM
or CEM CD4+ T cells were treated with 10 µM ABC and ABC ProTides. At 6, 24 and 48 h
after treatment, MDM or CEM CD4+ T cells were collected in 70% MeOH. CBV-TP from
MDM was extracted as previously described3, the samples were analyzed by LC-MS.
4.5.7 Preparation and Characerization of ABC ProTides LA nanosuspensions.
ABC ProTides LA nanosuspension were prepared by high-pressure homogenization
(Avestin EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada) as previously described.
Briefly, ABC ProTides (1% w/v), DSPE-mPEG2k (0.2% w/v) and Tween 80 (0.2% w/v) were
premixed in 10mM Phosphate buffer (pH 7.4) overnight at room temperature followed by
homogenization at 20,000 psi until the desired particle size and polydispersity index (PDI)
were achieved. Effective diameter (Deff), PdI, and ζ-potential were measured by dynamic
light scattering (DLS) (Malvern Zetasizer Nano Series Nano-ZS, Malvern Instruments,
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Westborough, MA, USA). Transmission Electron Microscope (TEM) was used to visualize
the morphology of nanosuspensions.
4.5.8 Cell uptake, retention and release of ABC ProTides LA nanosuspensions
Uptake, retention and release of ABC ProTides nanosuspensions were determined
with MDM as previously reported2,12,20-22. Briefly, MDM were treated with different
nanosuspensions at a concentration of 50 µM for various time. At 1, 2, 4 and 8 h, adherent
MDM were collected in 1 mL PBS after washing with 1 mL PBS twice. Then MDM were
pelleted by centrifugation at 3000rpm for 8 min. The cell pellet was reconstituted in 200 µl
methanol and probe sonication were briefly used to break the cells and help extract drugs.
After probe sonication, centrifugation at 14,000 rpm for 10 min were used to pellet the cell
debris. The supernatant was analyzed for prodrug content using HPLC. For retention and
release, MDM were treated with 50 µM different nanosuspension for 8 h. Then
nanosuspension contained media were replaced by fresh media after washing MDM with
PBS twice. Half media change was conducted every other day with whole media change
was conducted one day before collecting MDM. At day 1, 3, 7, 14, 21 and 28, MDM were
collected in 1mL PBS after washing with 1 mL PBS twice. The media were also collected
and stored in -20. The samples were processed as described above for analysis using
HPLC.
The intracellular levels of CBV-TP were also measured for cell uptake and retention
study. Briefly, after MDM were pelleted by 3000 rpm for 8 min, 200 µl 70% MeOH was
used for reconstitution. After the extraction of CBV-TP from MDM as previously reported3,
the samples were analyzed by LC-MS.
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4.5.9 In Vitro antiretroviral efficacy study with MDM.
The study was conducted as previously described2,12,20-22. MDM were treated with 50
µM different nanosuspension for 8 h. Then nanosuspension contained media were
replaced by fresh media after washing MDM with PBS twice. Half media change was
conducted every other day. At predetermined time point, days 1, 3 ,7, 14, 21 and 28, MDM
were infected with HIV-1ADA and cultured with half media changed for an additional 10
days. At days 10, supernatant was collected for RT assay and MDM were fixed and
immunostained for expression of p24. Untreated, uninfected MDM served as negative
controls (control), while MDM exposed to HIV-1ADA but not treated with nanosuspension,
served as positive controls (HIV-1).
4.5.10 In vivo pharmacokinetic study.
Animal PK studies were conducted in accordance with the University of Nebraska
Medical Center Institutional Animal Care and Use Committee. Male Sprague Dawley rat
(250g; Jackson Labs, Bar Harbor, ME) were injected intramuscularly (i.m.) with ABC,
NAlaC14, NAlaC18, NAlaC22 and NPheC18 (70 mg/kg ABC-eq.) intramuscularly (IM;
caudal thigh muscle). Whole blood samples were collected at 1 h, 1, 7, 14, 21 and 28 days
after injection. PBMC were separated from whole blood samples using HISTOPAQUE
1083 (Sigma# 1083-1) following manufacturer’s instruction.
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Figure 4.1 Design rationale and synthesis scheme of ABC ProTides LA.
A. Design rationale of ABC ProTides LA. Monophosphate group protected by an
aromatic group and an amino acid ester moiety, which can be enzymatically cleaved-off
inside cells to release the free nucleoside monophosphate and monophosphonate species
to increase the potency of drugs. Long-chain fatty alcohol of amino acid esters extend the
release of drugs. B. Synthesis scheme of ABC ProTides LA. Reagent and conditions:
a. long-chain fatty alcohol, HATU, imidazole, Et3N, DMF/CHCl3, 45 ℃, 48 h; b. Pd/C,
Et3SiH, MeOH/CHCl3 (1:1 v/v), rt, 16 h; c. Phenyl dichlorophosphate, Et3N, CH2Cl2, -78 ℃rt, 16 h; d. ABC, tert-BuMgCl, THF, -78 ℃- rt, 48-90 h.
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Table 4.1 Antiretroviral activity and cytotoxicity of ABC and ABC ProTides LA in
cell culturea

b

EC50 (μM) for
Cpd

b

c

Amino acid

c

CC50 (μM) for

SI

Esters
MDM

CEM CD4+

MDM

CEM CD4+

MDM

CEM CD4+

ABC

-

-

0.021

2.66

>400

>200

>19,000

>75

AlaC14

L-Ala

Myristyl

0.001

0.24

>100

>25

>100,000

>415

AlaC18

L-Ala

Stearyl

0.002

0.30

~400

>100

~200,000

~1330

AlaC22

L-Ala

Docosyl

0.004

2.19

>200

>200

>50,000

>90

PheC14

L-Phe

Myristyl

0.0002

1.21

~200

>12.5

>1,000,000

>10

PheC18

L-Phe

Stearyl

0.001

25.64

>400

>200

>400,000

>7.5

PheC22

L-Phe

Docosyl

0.003

43.03

~200

>200

~65,000

>4.5

CC50: 50% cytotoxic concentration.

SI (selectivity index) in= CC50/EC50
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AlaC14

AlaC18

AlaC22

PheC14

PheC18

PheC22

Figure 4.2 1H-NMR spectrum of ABC ProTides LA.
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AlaC14

AlaC18

AlaC22

PheC14

PheC18

PheC22

Figure 4.3 13C-NMR spectrum of ABC ProTides LA.
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AlaC14

AlaC18

AlaC22

PheC14

PheC18

PheC22

Figure 4.4 31P-NMR spectrum of ABC ProTides LA.

110

Figure 4.5 FT-IR Spectrum of ABC ProTides LA
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Figure 4.6 Intracellular CBV-TP levels.
Intracellular CBV-TP in MDM (A) and CEM CD4+ T cells. MDM or CEM CD4+ T cells
were treated with 10 µM ABC and ABC ProTides. At 6, 24 and 48 h after treatment, MDM
or CEM CD4+ T cells were collected in 70% MeOH. CBV-TP from MDM was extracted as
previously described3, the samples were analyzed by LC-MS.
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Figure 4.7 Metabolic stability of ABC ProTides LA in sera.
Metabolic stability of ABC ProTides LA in human serum (A) and rat serum (B).
The experiment was carried out by adding each ProTide into 300 μl human serum or rat
serum to reach a final concentration of 15 ug/ml in glass vial, and duplicate samples were
used for each ProTide. After incubating the samples at 37 °C with shaking for 6, 24 h, 1.5
ml of MeOH was added to stop the reaction. Samples were vortexed for 3 min, then
centrifuged down at 16,000 g for 10 min. The supernatants were transfer to new 2 ml tubes
and evaporated to dryness under vacuum. The samples were reconstituted using 50 μl of
MeOH, vortexed for 3 min and centrifuged down at 16,000 g for 10 min. The supernatants
were analyzed by HPLC for drug concentrations. For control sample (0 min), MeOH were
added first to stop the enzyme before adding the ProTides.
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Figure 4.8 Preparation and characterization of nanoformulated ABC ProTides
LA.

114

(A) Preparation of nanoformulated ABC ProTides LA. ABC ProTides LA
nanosuspension were prepared by high-pressure homogenization. ABC ProTides (1%
w/v), DSPE-mPEG2k (0.2% w/v) and Tween 80 (0.2% w/v) were premixed in 10mM
Phosphate buffer (pH 7.4) overnight at room temperature followed by homogenization at
20,000 psi until the desired particle size and polydispersity index (PDI) were achieved.
Effective diameter (Deff), PdI, and ζ-potential were measured by dynamic light
scattering (DLS) (B) TEM images of the morphology of nanoformulated ABC
ProTides LA.

115

Table 4.2 Characterization of nanoformulated ABC ProTides LA
ζ- potential

Drug loading

(mV)

(%)

0.20±0.03

-33.5±0.8

80%

242±2

0.28±0.04

--27.8±0.4

68%

NAlaC22

286±23

0.34±0.01

-32.1±1.5

79%

NPheC14

216±3

0.19±0.01

-37.5±1.2

74%

NPheC18

247±7

0.32±0.04

-38.4±2.9

50%

NPheC22

297±8

0.33±0.03

-39.0±3.0

53%

Name

Deff (nm)

PdI

NAlaC14

231±3

NAlaC18

Effective diameter (Deff), polydispersity index (PdI) and ζ- potential of nanoformulation
samples diluted in water were determined by dynamic light scattering (DLS). Drug
loadings of lyophilized nanoformulations were determined by HPLC. Drug loading (%) =
[entrapped drug/nanoparticles weight] x 100. Data are expressed as mean ± SD.
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Figure 4.9 Cell uptake, retention and release study in MDM.
For uptake study, MDM were treated with different nanosuspensions at a
concentration of 50 µM for various time. At 1, 2, 4 and 8 h, adherent MDM were collected
in 1 mL, pelleted by centrifugation, then reconstituted in 200 µl methanol or 70% MeOH
for prodrug (A) or CBV-TP (B) level measurements. For retention and release, MDM were
treated with 50 µM different nanosuspension for 8 h. Then nanosuspension contained
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media were replaced by fresh media after washing MDM with PBS twice. Half media
change was conducted every other day with whole media change was conducted one day
before collecting MDM. At day 1, 3, 7, 14, 21 and 28, MDM were collected in 1mL PBS,
pelleted by centrifugation, then reconstituted in 200 µl methanol or 70% MeOH for prodrug
(C) or CBV-TP (D) level measurements. The media were also collected for prodrug (E)
measurements.
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Figure 4.10 p24 staining of MDM for antiretroviral efficacy study.
MDM were treated with 50 µM different nanosuspension for 8 h. Then nanosuspension
contained media were replaced by fresh media after washing MDM with PBS twice. Half
media change was conducted every other day. At predetermined time point, days 1, 3 ,7,
14, 21 and 28, MDM were infected with HIV-1ADA and cultured with half media changed for
an additional 10 days. At days 10, supernatant was collected for RT assay and MDM were
fixed and immunostained for expression of p24. Untreated, uninfected MDM served as
negative controls (control), while MDM exposed to HIV-1ADA but not treated with
nanosuspension, served as positive controls (HIV-1).
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Figure 4.11 Pharmacokinetic study of nanoformulated ABC ProTides LA.
Male Sprague Dawley rat (250g; Jackson Labs, Bar Harbor, ME) were injected
intramuscularly (i.m.) with ABC, NAlaC14, NAlaC18, NAlaC22 and NPheC18 (70 mg/kg
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ABC-eq.) intramuscularly (IM; caudal thigh muscle). Whole blood samples were collected
at 1 hr, 1, 7, 14, 21 and 28 days after injection. PBMC were separated from whole blood
samples using HISTOPAQUE 1083 (Sigma# 1083-1) following manufacturer’s instruction.
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Chapter 5
Summary and Future Direction
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5.1 Summary
In this project, we proved that ProTide technology can be useful for the development
of ABC LA and be part of our LASER ART platform. ProTide technology was able to
increase the antiretroviral potency of drugs as compared to ABC. In general, L-alanine
based ProTides are more potent than L-phenylalnine based ProTides in CEM CD4+ T cells
but not in MDM. In MDM, L-alanine based ProTides had higher Cmax of CBV-TP within the
48 hr incubation, but L-Phenylalanine based ProTides had higher C48 of CBV-TP, which
can explain the results of EC50 in MDM. But in CEM CD4+ T cells, L-alanine based
ProTides had higher levels of CBV-TP for the whole 48 hr incubation. These results
correlated with the EC50 results and it is possibly due to the lack of certain enzymes in
CEM CD4+ T cells.
The presence of long-chain fatty alcohol diminished the improvement of potency
brought by ProTide technology, but some ABC ProTides stayed more potent as compared
to ABC. In general, there were significantly negative correlation between chain length of
fatty esters and drug potency against HIV-1. Besides that, ProTides with longer chain
length of fatty esters appeared to be more stable in serum which is very important since
presence of fatty acid esters improve membrane penetration of ProTides and will results
in higher prodrug levels inside the cell.
In summary, for the design of ABC LA with ProTides technology, there are at least two
balances need to be considered. First is the balance between potency and extended
release. Second is the balance between drug retained and released by MDM. At the end,
these are all determined by the amino acid side chain and chain length of fatty esters.
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5.2 Future directions
First of all, our ABC ProTides nanosuspension can be prepared using either poloxamer,
lipid derivatives, and tween as stabilizers. Different stabilizer might affect the
pharmacokinetics of nanosuspensions in vivo. For example, the presence of multinucleate
giant cells, prolonged macrophage infiltration of the formulation depot, and more persistent
histiocytic infiltrate in the lymph nodes were observed in the tween 80-containing
nanosuspension1, and these inflammation reactions not only can influence the overall
tolerability of LA nanosuspensions but also affect the pharmacokinetics of LA
nanosuspensions as macrophages served as secondary depots2. It is needed to optimize
our formulations by exploring different stabilizers.
Second, ProTides synthesized by general ProTides procedures yields a mixture of
diastereoisomers. In some case, the two ProTides diastereoisomers had similar potency
and can be pursued as mixtures. In other cases, one is more potent than the other
because of different metabolism rates. For instance, the Sp diaestereoisomer of tenofovir
alafenamide is 10-fold more potent against HIV than the Rp diastereoisomer3. Similar
phenomenon was also reported for ABC ProTides4. In order to further improve the potency
of ABC ProTides LA, it might be needed to separate diaestereoisomers or conduct
asymmetric synthesis5.
Third, species differences are well known and will affect the results of
pharmacokinetics study for our LA formulations. First, the metabolic rates are different in
different species. Faster clearance of RPV from muscles or skin in rats than dogs have
been observed. Second, muscle structures are different between species. Dogs have
softer and more vascularized striated muscle, which results in great spreading and faster
distribution of nanosuspension toward the blood circulation after IM administration. In rats,
IM injections are often not truly IM due to their small muscles and therefore more
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comparable with SC injections6, Third, the expression of enzyme is different among
species. For example, Paraoxonase (PON) and butyrylcholinesterase (BChE) were
ubiquitous in all species, but were highly expressed in primates and dogs, whereas
carboxylesterases (CES) were only abundant in rabbits, mice and rats. And CES are very
important for the degradation and activation of ABC ProTides and other prodrugs for LA
formulation developments7.
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